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Objective:  
To evaluate the correlation between the radiation dose to the pharyngeal constrictors 
and swallowing dysfunction using subjective and objective assessment, in patients 
with head and neck cancer undergoing radiation therapy alone or concurrent chemo 
radiation therapy. 
 
Methods and materials:  
Patients diagnosed to have head and neck cancers and planned for definitive or 
adjuvant radiation therapy (RT) with IMRT, with or without chemotherapy were 
screened and 14 patients were included in the study after meeting the inclusion and 
exclusion criteria. Subjective assessment to assess the Quality of life (QoL) was done 
using MD Anderson Dysphagia Inventory (MDADI). Objective assessment of 
dysphagia was performed with Functional Endoscopic evaluation of Swallowing 
(FEES). Both assessments were performed before starting RT, midway during the 
course of treatment and at the end of treatment. The dose volume effects of the 
pharyngeal constrictors were correlated with FEES assessment and MDADI scores. 
 
Results:  
Majority of the patients were male and majority had carcinoma of the buccal mucosa. 
No patient had complaints of dysphagia or radiological involvement of Pharyngeal 
constrictors before starting RT. Majority 64% (9/14) had impact on quality of life due 
to dysphagia at the end of RT, as assessed from MDADI score. 57% (8/14) had severe 
dysphagia with swallowing liquids and semisolids, as assessed by FEES. Patients with 
carcinoma of oropharynx, supraglottis and oral cavity received high mean doses and 
maximum doses to the pharyngeal constrictor muscles. Patients with severe dysphagia 
assessed by FEES had higher maximum doses to all the pharyngeal constrictors and 
higher mean dose to superior constrictor compared to those without dysphagia and this 
was statistically significant. High maximum and mean doses to pharyngeal 
constrictors were associated with poor quality of life as reflected from MDADI scores. 
 
 
Conclusion:  
Treatment of head and neck cancers with radiotherapy was associated with dysphagia 
that affects the quality of Quality of life. Severe dysphagia was common with patients 
who received high doses to pharyngeal constrictors, most significantly to the superior 
constrictor. Further studies are essential to assess severity of dysphagia in late setting. 
 
Key Words: Head and neck Cancer, Dysphagia, Pharyngeal constrictors, IMRT, 
FEES, MDADI, Quality of life. 
  
1. INTRODUCTION 
 
Head and neck cancers are a major cause of morbidity and mortality throughout the 
world. In India the incidence of head and neck cancers are very high and it is the third 
most commonly diagnosed malignancy after breast and cervical cancers.(1) 
Management of early stage head and neck cancers require a single modality where as 
multi modality approach is essential for advanced stage head and neck cancers. 
Radiation therapy which is an important modality in cancer treatment particularly in 
head and neck cancer has gone through significant evolution. It started with 
conventional radiotherapy using the Cobalt therapy unit and has evolved to conformal 
therapy using Linear Accelerator with 3DimensionalConformal Radiation Therapy 
(3DCRT) and Intensity Modulated Radiation Therapy (IMRT). IMRT has become the 
standard of care in delivering radiation therapy for head and neck cancers as it helps to 
minimize dose  to normal structures close to the target site, with dose escalation to the 
tumour at the same time.(2)(3) 
Head and neck cancers treated with radiation therapy can cause significant morbidity 
post treatment in the form of mucositis, xerostomia and dysphagia. Although IMRT 
can help in reducing dose to the salivary glands and reduce xerostomia and dysphagia, 
its role in preventing dysphagia by reducing dose to pharyngeal structures and 
constrictor muscles are controversial. 
This study therefore was carried out to evaluate the correlation between radiation dose 
to the pharyngeal constrictors with subjective and objective assessment of swallowing 
dysfunction in patients with head and neck cancers undergoing treatment with IMRT. 
  
2. AIMS AND OBJECTIVES 
 
AIMS 
 
To evaluate the correlation between the radiation dose delivered using Intensity 
Modulated Radiation Therapy (IMRT) technique to the pharyngeal constrictors and 
swallowing dysfunction using subjective and objective assessment, in patients with 
head and neck cancer undergoing radiation therapy alone or concurrent chemo 
radiation therapy. 
 
OBJECTIVES: 
 
Primary : To evaluate the association between the radiation dose delivered using 
Intensity Modulated Radiation Therapy (IMRT) technique to the pharyngeal 
constrictors and swallowing dysfunction (early dysphagia and aspiration) in patients 
with head and neck cancers undergoing radiation therapy alone or concurrent chemo 
radiation therapy. 
 
Secondary: To assess the Quality of Life (QoL) of patients undergoing radiation 
therapy, delivered using Intensity Modulated Radiation Therapy (IMRT) technique, 
either as radical radiotherapy alone or postoperative radiation therapy alone or with 
chemotherapy, using MD Anderson Dysphagia Inventory (MDADI). 
 
 
  
3. LITERATURE REVIEW: 
 
Head and neck squamous cell carcinomas are common malignancy with worldwide 
incidence of more than 550,000 new cases per year in different sub sites of head and 
neck.(4) It has wide variation considering different anatomic sites and different 
etiologic factors. Hence head and neck cancers consist of a very heterogeneous 
group.(5) 
The WHO GLOBOCAN Report 2012 also reported a very high 5 year prevalence rate 
for head and neck cancers in India. Lip &Oral cavity cancers have a 5 year prevalence 
rate of 12.6%, while for Laryngeal cancers it is 6.8%, Nasopharynx 1.1% and other 
pharynx 7%. This shows the high burden of head and neck cancers in India with 5 
year prevalence rates of nearly 27%.(6) 
India does not have a National Cancer Registry that records comprehensive 
information regarding the cancer incidence or mortality data in India. The National 
Cancer Registry Programme (NRCP) was started in 1981 by the Indian Council of 
Medical Research (ICMR). This registry provides information regarding 28 cancer 
registries located throughout the country. The cancer registries have been classified as 
population based cancer registries and hospital based cancer registries. Based on the 
reports of the 7 hospital based cancer registries, head and neck malignancies 
accounted for around 30% of all cancers in males (table 1) and about 11 % in females. 
In Chennai the prevalence of Head and neck cancer is about 28% in males and about 
11% in females as shown. 
 
  
 
 
 
 
 
 
 
 
 
Table 1 showing prevalence of head and neck cancer in India 
The most common head and neck cancers seen in India are tongue and mouth cancers 
followed by pharyngeal cancers, which is commonly attributable to tobacco chewing 
practices prevalent in various parts of the country.(7)(1) 
 
3.1. AETIOLOGY OF HEAD AND NECK MALIGNANCY 
 
The most common causes of head and neck malignancies includes consumption of 
tobacco and tobacco products, alcohol consumption, Human Papilloma Virus 
infection, dietary factors, exposure to chemicals, precancerous conditions and some 
other factors like sharp tooth and consumption of spicy food. Amongst all these, 
consumption of tobacco and tobacco products are the commonest cause. The high 
prevalence of head and neck malignancies was seen with high consumption of 
tobacco.(8)Cigarettes, cigars, pipes, bidis and hukkas are the various forms in which 
tobacco is used for smoking. There are several forms of smokeless tobacco which 
  
have high consumption rates and form a major causative agent for head and neck 
malignancies. Commonly used forms of smokeless tobacco are tobacco leaves (for 
chewing), moist snuff, paan or betel quid and gutkha. All these tobacco products have 
been found to have carcinogens and have been implicated in the causation of a large 
number of malignancies including head and neck malignancies.(7)(9) 
 
The other important factor in causation of head and neck malignancies is consumption 
of alcohol. It has been linked to vitamin deficiencies and that also leads to the 
causation of head and neck malignancies. Consumption of alcohol along with tobacco 
smoking increases the risk of head and neck malignancies by many folds and has got a 
synergistic effect. While cigarette smoking and alcohol are the main reasons of head 
and neck squamous cell cancers in Western countries, it is the smokeless tobacco like 
khaini, pan, zarda that are common in Asian countries.(10)(11)Head and neck cancers 
also show field cancerization, where synchronous primary cancers are seen in the 
entire mucosal tract of the head and neck region. (12) This is common in people who 
both smoke and drink alcohol, as it causes the entire mucosal tract of the head and 
neck region to be exposed to carcinogens. (13) 
 
Human Papilloma virus 16 (HPV 16) also plays an important role in head and neck 
cancers, particularly in oral cavity and oropharyngeal cancers. HPV is a virus that 
affects squamous epithelial cells. This virus is found in the genitourinary tract and is a 
major causative factor in the causation of cervical cancers. However, in the past few 
years, it has also been seen to be associated with a variety of head and neck cancers, 
  
especially the oropharyngeal cancers (tonsils, tonsillar fossa, base of the tongue, and 
soft palate). (14)The reason for the increase in the incidence of HPV associated oral 
cancers is the sexual practice of genito-oral sex. Cigarette smoking plays an additive 
role in the causation of these cancers associated with HPV. (15) 
 
Nasopharyngeal cancers are found to be associated with Epstein Barr viruses (EBV). 
The incidence of nasopharyngeal cancers is high in areas endemic for the Epstein Barr 
Virus.(16) EBV titres are nowadays used for determining the tumour burden at the 
time of diagnosis and have high sensitivity and specificity in diagnosing 
nasopharyngeal cancers. (17) The EBV DNA titres also play a prognostic role and 
high titres are associated with a poorer prognosis. (18)Even post treatment EBV DNA 
titres are associated with high chance of recurrence.(19) 
 
There are many precancerous conditions that play an important role in the causation of 
head and neck cancers. (20) Leucoplakia and erythroplakia are the two most important 
premalignant lesions which can transform into invasive carcinoma of the oral cavity.  
The other lesions which have also been implicated are submucosal fibrosis, actinic 
keratosis and lichen planus. Erythroplakia has twenty times more chances for 
transformation into invasive cancer when compared to leucoplakia.(21) Other factors 
which have been found to be important in the causation of head and neck cancers are 
some dietary factors which includes spicy food, sharp teeth and exposure to certain 
chemicals.(13) 
  
3.2. NATURAL HISTORY OF HEAD AND NECK MALIGNANCY 
 
Most of the cancers of the head and neck region are malignant epithelial tumours. 
Squamous cell carcinoma is the most common histology seen. These tumours usually 
begin as surface lesions, but occasionally originate below the surface of the mucosa. 
The propensity to spread depends on local anatomy and thus varies according to each 
site. Muscular invasion is common, and tumour may spread along muscle or fascial 
planes. Tumours may attach to the periosteum but bone or cartilage invasion is a late 
event as bone and cartilage usually act as a barrier to spread. Tumours that encounter 
these structures are often diverted and spread along a path of less resistance. (22) 
 
Tumour extension into the parapharyngeal space allows superior or inferior spread 
from the skull base to the low neck. Perineural invasion (PNI) is observed in 
squamous cell carcinomas as well as salivary gland tumours, especially adenoid cystic 
carcinomas. The presence of PNI predicts a poorer rate of local control. Tumours may 
track along a nerve to the skull base and central nervous system. Patients with PNI 
may develop neurologic symptoms secondary to nerve invasion or due to entrapment 
of the nerve. Vascular space invasion is associated with an increased risk for regional 
and distant metastases.  
 
The risk of lymph nodal metastasis can be predicted by the differentiation of the 
tumour, size of the primary lesion, presence of vascular space invasion, and density of 
capillary lymphatic. Recurrent lesions have an increased risk of lymph nodal 
  
involvement. The histology of the tumour also influences the likelihood of lymphatic 
spread. Low-grade minor salivary gland tumours and sarcomas have a lower risk of 
lymph node metastases than squamous cell carcinomas.  
 
The relative incidence of clinically positive lymph nodes is determined by the primary 
site and T stage of the tumour. Well-lateralized lesions spread to ipsilateral neck 
nodes. Lesions on or near the midline, tongue base and nasopharyngeal lesions, may 
spread to both sides of the neck, although the risk is higher to the side occupied by the 
bulk of the lesion. Patients with clinically positive ipsilateral neck nodes are at high 
risk for contralateral disease, especially if the nodes are large or multiple. The 
likelihood of retropharyngeal adenopathy is related to the presence of clinically 
involved lymph nodes and primary site, and is particularly high for nasopharyngeal 
carcinomas.  
The risk of distant metastasis is related mostly to the nodal stage of the disease. The 
risk is less than 10% for node negative disease and rises to approximately 30% for 
node positive disease. It is also higher in the presence of nodes below the level of the 
thyroid notch. The lung is the most common site, accounting for nearly half of the first 
recognized distant metastases 
 
 
  
 
3.3. HISTOLOGY OF HEAD AND NECK MALIGANANCY 
 
 
The World Health Organization (WHO) has given a classification for the histological 
classification of head and neck tumours.(23) Amongst all of these tumours, squamous 
cell carcinomas and its variants (lymphoepithelioma, spindle cell carcinoma, 
verrucous carcinoma, and undifferentiated carcinoma) are the most common epithelial 
malignancies seen in head and neck region. Other tumours which are also commonly 
seen are salivary gland tumours, lymphomas and sarcomas. However, the incidence of 
these tumours is very less as compared to squamous cell carcinomas.  
 
3.4. EVALUATION AND DIAGNOSIS 
 
Patients presenting with a likely diagnosis of head and neck malignancy should 
undergo a thorough history, general medical evaluation, including a thorough head 
and neck examination. The location and extent of the primary tumour with its 
dimensions and any clinically positive lymph nodes should be carefully noted. 
Clinical examination of the primary involves assessing the type of lesion 
(proliferative, infiltrative and ulcerative), extent and involvement of underlying 
structures. Examination under anaesthesia (EUA) is also performed for deep lesions 
that are difficult to assess. 
 
Fine needle aspiration cytology (FNAC) is commonly done for head and neck cancers 
with neck nodes.  FNAC is easy to perform, relatively cheap and with less discomfort 
  
can be done in an outpatient basis. FNAC has a high sensitivity and specificity with a 
diagnostic accuracy range of 88% to 98%. (24) Non diagnostic aspirations can occur 
in 5%-15% of the cases where the neck nodes are cystic, commonly found in HPV 
associated oropharyngeal cancers.(25)Ultrasound guided FNAC or trucut biopsy or 
excision biopsy of the lymph node is done when repeat FNACs are negative, if there is 
no obvious primary in the head and neck region or the biopsy from primary is difficult 
and needs to be done under anaesthesia or requires a tracheostomy. 
 
Evaluation with the help of Naso-pharyngo-laryngoscopy (NPL scopy) is essential for 
the purpose of assessing the extent of the primary lesion. This is particularly helpful in 
nasopharyngeal, laryngeal and hypopharyngeal malignancy. 
 
Ultrasonography (USG) evaluation of the neck nodes(26) is essential in evaluation for 
neck nodes in patients with head and neck cancers as it changes the treatment plan and 
affects prognosis. Metastatic lymph nodes in head and neck cancers are site specific 
and depend on the location of the primary tumours most often.USG helps in 
identification of metastatic nodes with the following features  
a. Size: size is one of the most important features to distinguish between reactive 
and malignant node. Generally malignant nodes tend to be larger than the 
reactive nodes. In head and neck malignancy nodes above 10mm are 
considered to be significant according to size criteria. 
b. Shape: metastatic nodes tend to be round with ratio of short axis to long axis 
tends be more than 0.5.Apart from the size, eccentric cortical hypertrophy that 
  
occurs due to focal tumour infiltration with a lymph node is also a diagnostic 
feature of malignant neck nodes.(27) 
c. Metastatic neck nodes tend to have sharp borders 
d. They are predominately hypo echoic compared to surrounding structure. 
Metastatic node from thyroid malignancy may be echogenic due to presence of 
thymoglobulin. They tend to have calcification unlike benign nodes. 
e. Although ancillary feature like matting is common with Tuberculosis, 
metastatic lymph nodes with diffuse oedema from the primary or pre radiated 
area may show similar features. 
 
A contrast enhanced computed tomography (CECT) and/or magnetic resonance 
imaging (MRI) is commonly done to define the extent of locoregional disease. In most 
cases, CT scan is sufficient and the use of an MRI is reserved only in cases of very 
early disease. MRI defines the extent of the disease and the soft tissue involvement 
and help in planning surgery as they give a better delineation of the soft tissues and 
the extent of the tumour into adjacent structures, fascia, muscles, vessels and nerves. 
MRI scans are of particular importance in Parotid gland malignancies where the 
incidence of perineural spread is very high. They can help in visualising the spread of 
the tumour along the nerves. MRI is also helpful in assessing the skull based marrow 
invasion, dural invasion, cavernous sinus invasion and retropharyngeal adenopathy. In 
oral cavity malignancy contrast enhanced MRI helps in accurate extent of tumour 
within the tongue.  Involvement of pre vertebral fascia, characterisation of benign and 
  
malignant salivary gland tumours, recurrence from post treatment changes, features of 
Paranasal sinuses are other important aspects where MRI is essential. 
Contrast CT is essential in gingival, retromolar trigone and buccal cavity lesions as 
bone erosions are common in this type of malignancy. In the infrahyoid compartment 
faster speed in CT imaging helps in better visualizations of laryngeal and 
hypopharyngeal malignancy preventing motion artefacts due to swallowing, that 
happens in MRI scan.(28) However Diffusion Weighted MRI is often helpful in to 
detect thyroid cartilage invasion in laryngeal cancers.(29) 
 
The role of a PET scan (Positron Emission Tomography) has been shown to be very 
useful in the diagnosis of primary tumour as well as recurrences during follow up 
visits. It has high negative predictive value of 95% to rule out viable disease at the 
time of follow up. In advanced malignancy it helps to detect the extent of neck nodes 
and can detect up to 27 % of unknown primaries. The PET scans fused with CT scans 
gives a better delineation of the anatomical and functional imaging aspects of the 
tumor and can be used for diagnostic purposes also. They are especially important in 
detection of metastasis of neck nodes. However, the biggest problem in a PET scan is 
the non-uniformity of SUV (Standardised Uptake values). Also, the most common 
tracer used in PET scans is FDG (Flourine deoxy Glucose) which accumulates in 
areas of high glucose metabolism. Thus, areas of necrosis and hypoxia in the tumours 
are missed with the use of this tracer as there is no glucose metabolism in these areas.  
 
  
A chest radiograph should be obtained in all cases to rule out lung metastasis and also 
to rule out a synchronous primary lung cancer. In case of any suspicion on the chest 
radiograph, a CT scan of the thorax is indicated for proper characterization of the lung 
parenchyma. The use of bone scan for evaluation of osseous metastasis is common for 
nasopharyngeal malignancy. Besides bone scan, USG abdomen is done to assess liver 
metastasis in cases of locally advanced head and neck cancers. Whole body PET CT 
scan can also be utilised for evaluate for systemic metastasis. 
 
Before initial treatment, the patient should be evaluated by members of the team who 
may be involved in the management as well as possible salvage therapy. Head and 
neck surgeons, radiation oncologists, medical oncologists, diagnostic radiologists, 
plastic surgeons, pathologists, dentists, speech and swallowing therapists, and social 
workers may all play a role. The treatment options are discussed and 
recommendations are presented to the patient who makes the final decision. 
 
3.5. STAGING OF HEAD AND NECK CANCERS 
 
The different sub sites of head and neck cancers are staged differently based on TNM 
classification. This classification was first devised by Pierre Denoix between 1943 and 
1952. This was further developed and maintained by the Union for International 
Cancer Control to achieve global consensus regarding staging of cancers. (30) 
Currently the 7
th
 edition has been published in 2009 and adopted for practice from 
2010 onwards.(31) The staging mentioned below is taken from AJCC- TNM 
classification(32) of malignant tumours published in seventh edition 2009. 
  
The cancer of the head and neck are staged as follow 
Staging of Lip and Oral cavity 
T – Primary Tumour 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1- tumour that is 2 cm or less in greatest dimension 
T2- tumour that is more than 2cm but less than 4cm in greatest dimension 
T3-tumour more than 4cm in greatest dimension 
T4a(lip) tumor invades through cortical bone, inferior alveolar nerve, floor of 
the mouth or skin of the chin or nose. 
T4b (oral cavity) tumour invades the cortical bone, involving deep/extrinsic 
muscle of tongue, maxillary sinus or skin of the chin or nose 
T4b (lip and oral cavity) tumour invades masticator space, pterygoid plates, or 
skull base of involves internal carotid artery 
 
 
 
N- Regional Lymph nodes 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph node,3cm or less in greatest 
dimension 
N2 Metastasis as described below: 
N2a Metastasis in a single ipsilateral lymphnode, more than 3 cm but not more 
than6 cm in greatest dimension 
N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in 
greatest dimension 
N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm 
in greatest dimension 
N3 Metastasis in a lymph node more than 6 cm in greatest dimension 
 
 
 
M – Distant Metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
 
 
  
 
Staging of the Pharynx  
Staging of Nasopharynx 
 
T1 Tumour confined to the Nasopharynx, or tumour extends to oropharynx 
and/or nasal cavity without parapharyngeal extension 
T2 Tumour with parapharyngeal extension 
T3 Tumour involves bony structures of skull base and or Paranasal sinuses 
T4 Tumour with intracranial extension and/or involvement of cranial nerves, 
hypopharynx, orbit, or with extension to the infratemporal fossa/masticator 
space 
 
Staging of Oropharynx 
 
T1 Tumour 2 cm or less in the greatest dimension 
T2 Tumour more than 2 cm but not more than 4 cm in the greatest dimension 
T3 Tumour more than 4 cm in greatest dimension or extending to lingual 
surface of the epiglottis 
T4a Moderately advanced local disease with invasion of larynx, extrinsic 
muscle of tongue, medial pterygoid, hard palate, or mandible 
T4b Very advanced local disease with invasion of lateral pterygoid muscle, 
pterygoid plates, lateral nasopharynx, or base of the skull or encasing the 
carotid artery 
 
Staging of the Hypopharynx  
 
T1 Tumour limited to one subsite of hypopharynx and or 2 cm or less in the 
greatest dimension 
T2 Tumour invades more than one subsite of the hypopharynx or an adjacent 
site, or measures more than 2 cm but not more than 4 cm in greatest dimension 
without fixation of hemilarynx 
T3 Tumour more than 4 cm in greatest dimension or with fixation of hemi 
larynx or extension to esophagus 
T4a Moderately advanced local disease with tumor invading thyroid or the 
cricoids cartilage, hyoid bone, thyroid gland, or central compartment soft 
tissue 
T4b Very advanced local disease that invades prevertebral fascia, encases 
carotid artery, or involves mediastinal structures 
 
  
 
N- Regional nodes for Nasopharynx 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest 
dimension, above the supraclavicular fossa, and/or unilateral or bilateral, 
retropharyngeal lymph nodes, 6 cm or less, in greatest dimension 
N2 Bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest 
dimension, above the supraclavicular fossa 
N3 Metastasis in a lymph node(s) >6 cm and/or to supraclavicular fossa 
N3a Greater than 6 cm in dimension 
N3b Extension to the supraclavicular fossa 
 
 
 
 
 
Regional Nodes for Oropharynx and Hypopharynx 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in the greatest 
dimension 
N2 Metastasis in single ipsilateral lymph node, more than 3 cm but not more 
than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none 
more than 6 cm in greatest dimension, or in bilateral or contralateral lymph 
nodes, none more than 6 cm in greatest dimension 
N2a Metastasis in a single ipsilateral lymph node more than 3 cm but not more 
than 6 cm in greatest dimension 
N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in 
greatest dimension 
N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm 
in greatest dimension 
N3 Metastasis in a lymph node more than 6 cm in greatest dimension 
 
 
 
 
 
 
 
  
 
 
 
Primary Tumour (T) Supraglottis 
TX Primary Tumour cannot be assessed 
T0 No evidence of primary Tumour 
Tis Carcinoma in situ 
T1 Tumour limited to one subsite of supraglottis with normal vocal cord 
mobility 
T2 Tumour invades mucosa of more than one adjacent subsite of supraglottis 
or glottis or region outside the supraglottis (e.g., mucosa of base of tongue, 
valleculae and medial wall of pyriform sinus) without fixation of the larynx 
T3 Tumor limited to larynx with vocal cord fixation and/or invades any of the 
following: post cricoid area, pre epiglottic space, paraglottic space, and/or 
inner cortex of thyroid cartilage 
T4a Moderately advanced local disease that invades through the thyroid 
cartilage and/ or invades tissues beyond the larynx (e.g., trachea, soft tissues of 
neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or 
esophagus) 
T4b Very advanced local disease invading prevertebral space, encases carotid 
artery, or invades mediastinal structures 
 
Glottis 
T1 Tumour limited to the vocal cord(s) (may involve anterior or posterior 
commissure) with normal mobility 
T1a Tumour limited to one vocal cord 
T1b Tumour involves both vocal cords 
T2 Tumour extends to supraglottis and/or subglottis, and/or with impaired 
vocal cord mobility 
T3 Tumour limited to the larynx with vocal cord fixation and/or invasion of 
paraglottic space, and/or inner cortex of the thyroid cartilage 
T4a Moderately advanced local disease invading through the outer cortex of 
the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, 
soft tissues of neck including deep extrinsic muscle of the tongue, strap 
muscles, thyroid, or esophagus) 
T4b Very advanced local disease invading prevertebral space, encases carotid 
artery, or invades mediastinal structures 
 
 
 
  
 
 
 
Subglottis 
T1 Tumour limited to the subglottis 
T2 Tumour extends to vocal cord(s) with normal or impaired mobility 
T3 Tumour limited to larynx with vocal cord fixation 
T4a Moderately advanced local disease invading the cricoid or thyroid 
cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of 
neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or 
esophagus) 
T4b Very advanced local disease invading the prevertebral space, encases 
carotid artery, or invades mediastinal structures 
 
 
Regional Lymph Nodes (N) 
 
NX Regional lymph nodes cannot be assessed N0; no regional lymph node 
metastasis 
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest 
dimension 
N2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not more 
than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none 
more than 6 cm in greatest dimension, or in bilateral or contralateral lymph 
nodes, none more than 6 cm in greatest dimension 
N2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not 
more than 6 cm in greatest dimension 
N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in 
greatest dimension 
N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm 
in greatest dimension 
N3 Metastasis in a lymph node, more than 6 cm in greatest dimension 
 
  
  
3.6. OVERVIEW OF THE MANAGEMENT OF HEAD AND NECK CANCER 
 
The management of head and neck cancer depends on the site, stage of the disease 
along with general condition of the patient. The different sub sites in head and neck 
cancers have a different prognosis depending on stage, histology and anatomical 
location of the tumour. It is mostly the T stage of the disease and the presence or 
absence of nodal metastasis which serve as important prognostic factors related to 
survival. Other factors which have been seen to be important prognostic indicators are 
the histology of the tumour and occasionally the sex predilection of tumour.  
Advanced T stage is associated with worse local control and overall survival. Also 
advanced N stage predicts increased risk of distant metastasis and worse survival. 
Presence of distant metastasis (M1) at the time of presentation indicates poor 
prognosis. The presences of bone erosion, cranial nerve palsy or lower nodal level are 
all poor prognostic factors. Histology wise, non keratinizing and undifferentiated 
carcinomas are more radiosensitive and have a better prognosis than keratinizing 
squamous cell carcinoma 
Early stage head and neck cancers are managed with single modality like surgery or 
radiotherapy but locally advanced requires a combination of modalities of therapy. 
The selection of the modality depends on the site, stage, operability and general 
performance of the patient.  Surgery is the mainstay of the treatment for early stage 
head and neck cancers and radiation therapy is required only if risk factors are 
present.(33) Sometimes radiation therapy alone is used for management of early stage 
cancer as surgery increases the morbidity and quality of life and also if the patient is 
  
unwilling or medically unfit for surgery. In locally advanced head and neck cancers 
the management involves a multimodality approach with definitive chemo 
radiotherapy or surgery followed by radiotherapy with or without chemotherapy based 
on HPE. Trials have consistently demonstrated that combined treatment of radiation 
therapy with concurrent Cisplatin whenever indicated is superior compared to only 
radiation therapy in terms of local tumour  control and overall survival.(36).In very 
advanced stage disease; palliative radiation therapy is also used to control the 
symptoms. 
 
3.6.1. SURGERY 
 
Surgery is one of the modalities of treatment in treatment of head and neck cancers. 
The primary goal of surgery is to remove the tumour with adequate margins at the 
same time retain the functionality of individual organs. Minimally invasive surgery 
may be used for early stage disease. Locally advanced carcinoma requires adjuvant 
treatment after surgery. Unresectable tumours can be defined as those tumours that 
cannot be removed without unacceptable toxicities, as mentioned in NCCN 
guidelines. Tumours that involve the cervical vertebra, skin, brachial plexus, deep 
muscles of the neck or carotid artery are considered inoperable as complete removal 
of the tumour is not possible on anatomic grounds.  
Along with the primary tumour resection, neck dissection is also performed. 
Historically neck dissection was classified as radical or modified radical procedure. 
  
Presently the procedure is classified as selective neck dissection or comprehensive 
neck dissection. The final HPE of primary tumour and neck dissection determines the 
adjuvant treatment (chemo radiation therapy or radiation therapy).(37) 
In general compared to radiation therapy, surgery involves limited amount of tissue 
exposed to treatment, shorter treatment time and less late treatment complications. 
Achieving an adequate margin during surgical resection is of utmost importance. 
Adequate margin is defined as clear resection margin with at least 5mm or more from 
the invasive tumour. Close margins is defined as one less than 5mm. 
 
3.6.2. POST OPERATIVE RT WITH OR WITHOUT CHEMOTHERAPY 
 
The role of adjuvant therapy in post operative patients depends on risks factors as 
shown in clinical trials RTOG 9501 and EORTC22931. (38)(39) Both the trials showed 
that patients with extra capsular nodal spread and or positive margins had improved 
overall survival with chemoradiation therapy compared to radiation therapy alone. 
Patients with multiple regional nodes but without any extra capsular spread did not 
show any survival benefit with addition of chemotherapy to radiation therapy. 
Indications of only post operative radiation therapy are multiple positive nodes, pT3 
or T4 primary disease and positive level 4 and 5 nodes in oral cavity and 
oropharyngeal carcinomas. Commonly used chemotherapy is Cisplatin. Carboplatin or 
biological therapy can also used in case of poor performance status of the patients. 
  
3.6.3. CHEMORADIATION 
 
The rational for combining chemotherapy with radiation therapy in treatment for head 
and neck cancer is to sensitize the tumour to radiation therapy by inhibiting tumour 
repopulation, killing hypoxic cells and sterilizing micro metastatic disease outside the 
radiation field. Fractionated radiation therapies also in return sensitize tumours to 
chemotherapy by inhibiting the repair of drug induced damage. 
With this concept in mind there were early trials that showed the benefits of chemo   
radiation therapy. Aldestein et al (40)showed that patients with unresectable head and 
neck cancers when with treated with concurrent chemo radiation therapy reported to 
have increased median survival compared to those with only radiation therapy alone. 
RTOG 91-11 trial also showed that larynx preservation rate and locoregional control 
was significantly improved with concurrent chemo radiation therapy compared to 
induction chemotherapy or radiation therapy alone.(39) 
Hence in a patient with locally advanced head and neck cancer, combined modality 
with radiation therapy and chemotherapy is the standard of care. 
 
3.6.4. CHEMOTHERAPY 
 
Chemotherapy in head and neck cancer can be used as neoadjuvant therapy, 
concurrent with radiation therapy or as palliative therapy. 
  
The history of use of chemotherapy started long ago, with single agent chemotherapy 
or combination chemotherapy along with radiation therapy.  Chemotherapeutic agents 
like Mitomycin, 5 Fluouracil had severe toxicities when used with radiation therapy. 
(40) Of all the agents, Cisplatin became the drug of choice for use concurrently with 
radiation therapy. Trials with concurrent chemotherapy Cisplatin showed significant 
benefit in head and neck cancers. The MACH-NC meta-analysis showed the benefit of 
adding concurrent chemotherapy to radiation therapy in head and neck cancers and 
results showed an improvement in overall survival rates at 5 years with the addition of 
concurrent chemotherapy.(41) 
There is also a role of neoadjuvant chemotherapy in locally advanced head and neck 
cancers. Neoadjuvant chemotherapy downsizes the tumour that further helps in 
surgery or radiation therapy. The TAX 323 and 324 trials (42) show that in locally 
advanced unresectable head and cancers, neo adjuvant chemotherapy with Docetaxel, 
Cisplatin and 5-Fluorouracil, had long term survival benefit in patients with 
unresectable disease.(43)(44) 
Chemotherapy with adjuvant radiation therapy after surgery is used for patients with 
high risk factors as mentioned above. (45)(46) 
In metastatic head and neck cancers chemotherapy is used as palliative agent. Drugs 
like Docetaxel, Paclitaxel, Gemcitabine, Methotrexate are used in palliative or 
recurrent head and neck cancers.(47)(48) 
  
 
3.6.5. BIOLOGICAL THERAPY 
 
Squamous cell carcinomas of the head and neck often over express epidermal growth 
factor receptor (EGFR).This high expression of EGFR is associated with poor 
prognosis. Cetuximab is a biological targeted therapy that binds to EGFR receptor. 
Boner et al showed that treatment of loco regionally advanced head and neck cancer 
with high dose radiotherapy and Cetuximab improves locoregional control and 
reduces mortality without increasing common toxic side effects.(49) Cetuximab is used 
for patients who cannot tolerate concurrent chemotherapy in view of poor 
performance status. 
Nimotuzumab is another biological agent targeting EGFR receptor that is 
demonstrated to be safe and effective when combined with chemotherapy or 
chemoradiation therapy in head and neck cancers(50). In metastatic head and neck 
cancers Tyrosine Kinase Inhibitors like Gefitinib is also used.(47) 
 
3.6.6. RADIATION THERAPY 
 
Radiation therapy is an important and potential curative modality in head and neck 
cancers. For locoregional disease RT is often used in combination with chemotherapy 
as definite organ preservation approach or after surgery as adjuvant therapy. 
 
  
CONVENTIONAL RADIATION THERAPY 
 
Radiation therapy has evolved from the conventional era of two dimensional 
conventional planning to the present day era of 3 dimensional conformal planning. 
Initially, patients were planned with 2 dimensional conventional methods of planning 
in which an X ray was taken to define the field borders. The field borders were placed 
depending on the anatomical extent of the tumour and the nodal spread of the disease. 
In the conventional planning methods, it is difficult to reduce the dose to the adjacent 
normal structures, without compromising the dose to the primary tumour. The 
radiation therapy beams deliver the same dose throughout to the primary tumour and 
to the adjacent normal structures. Customised blocks may be used to decrease the 
radiation dose to the normal tissue. However, the process of making customised 
blocks is very cumbersome and even with their use; the normal tissue still receives a 
very high dose. Thus, the therapeutic index for such a planning technique is very small 
with very high rates of complications due to increased radiation dose to normal tissue.  
 
CONFORMAL RADIATION THERAPY 
 
The concept modulating the fluence of the radiation beam to achieve a desired dose 
distribution was first given by Brahme et al in 1982. (51)(52)However, it was not till 
the early 21st century that fluence modulation was used in delivering radiation therapy 
beams. It was with the start of CT planning in radiation therapy which led to the 
development of Intensity Modulated Radiation Therapy (IMRT). Since the 
development of this modality of delivering radiation therapy, the most important 
  
aspect which has improved is the Therapeutic ratio. With the modulation of the dose 
fluence, it is now possible to give higher dose to the tumour and lesser dose to the 
normal tissue which is located in close proximity to the tumour. 
 
In head and neck malignancies, several critical organs at risk are found to be in very 
close proximity to the target volume. Also there is a lot of in homogeneity in the head 
and neck region which can affect the dose and delivery of radiation. Often depending 
on the site and extent of primary disease the tumour surrounds the normal tissues or 
lies in close proximity to critical structures and makes it difficult or impossible by 
conventional radiation therapy to deliver high doses to the tumour tissue without 
giving unacceptable doses to the adjacent normal structures. However, with IMRT, it 
is practically possible to decrease the normal tissue dose while delivering high dose to 
the tumour. One of the main advantages of IMRT in head and neck cancers is sparing 
of parotid gland and prevention of late xerostomia, at the same time escalate dose to 
the tumour.(53) Intensity Modulated Radiation Therapy (IMRT), thus, is presently 
considered the standard of care in managing head and neck malignancies. IMRT can 
be delivered using different methods like sequential two phases or single phase 
Simultaneous Integrated Boost (SIB) technique. 
 
All these techniques of delivering IMRT have the same treatment volumes comprising 
of the high risk volume (consisting of the area of tumour and area for high risk of 
disease spread) and a low risk volume (area which will be irradiated prophylactically 
to prevent the spread of the disease). In few instances like nasopharyngeal carcinoma, 
  
there is also an intermediate risk area identified which is treated to doses in between 
the high risk and low risk area. 
 
3.7. SIDE EFFECTS OF RADIOTHERAPY 
 
Improvement in the loco-regional control was largely due to intensification of the 
treatment with radiation therapy dose intensification and addition of chemotherapy. 
The improvement in overall survival was noted with several trials that studied 
concurrent chemo radiation therapy for head and neck malignancy. With increased in 
survival, the heath related to quality of life has become very important to these 
patients.  Patients expect a good quality of life without any compromise in treatment 
outcomes following the treatment of head and neck cancers. There are many side 
effects that happen during as well as after the course of radiation therapy. Common 
side effects following the radiation therapy to head and neck cancer patients occur as 
early and late side effects. The chances of these complications and its severity depend 
on a number of factors including total dose of radiation delivered, time and the region 
where radiation therapy was received(54). These side effects can be described as 
follows: 
a. Xerostomia 
b. Mucositis 
c. Candidiasis 
d. Dysguesia 
e. Dental caries 
f. Osteroradionecrosis 
  
g. Trismus  
h. Oral Pain  
i. Dermatitis, soft tissue fibrosis 
j. Dysphagia 
Out of all these problems, xerostomia and dysphagia are common problems that 
happen in patients undergoing radiation therapy both as acute and late effect of 
radiation therapy. 
a. Xerostomia: It is also known as dryness of the mouth due to decreased saliva 
secretion and is one of the most common of all the side effects for patients 
receiving radiation therapy. (55) Xerostomia occurs as major and minor salivary 
glands in our body are damaged due to radiation therapy for the cancer 
treatment. The problems associated with xerostomia include difficulty to speak, 
difficulty in eating and increased risk of dental caries. Saliva helps to protect 
the teeth and absence of saliva in there is increased in chances of dental caries 
formation. The use of IMRT technology in radiation therapy has greatly 
reduced xerostomia(56). The PARSPORT trial which is a Phase III randomised 
trial showed that radiation therapy with IMRT reduces patient reported 
xerostomia, allows recovery of salivary flow and improves the quality of life 
after treatment in head and neck cancers, compared to conventional radiation 
therapy. Xerostomia can be treated by mechanical or taste stimulants, saliva 
substitutes and systemic therapy. Alternative methods like acupuncture have 
also been used to reduce xerostomia. While systemic therapy such as use of 
Pilocarpine increase the salivary flow, saliva substitutes improve the 
  
xerostomia without any effect of salivary hypo function. The use of Pilocarpine 
has been most useful when used during radiation therapy(57). 
 
b. Dysphagia: It is defined as difficulty to swallow solids or liquids. This can 
happen if the primary disease in head and neck cancers causes impairment in 
functioning of the swallowing structures as well or as a complication due to 
treatment. Dysphagia is often an underestimated problem in head and neck 
cancer patients.(58) Surgery for locally advanced cancer can cause swallowing 
problems by limiting the actions of various muscles associated with 
swallowing. Further radiation therapy after surgery produce radiation induced 
fibrosis, dysphagia and xerostomia that increase the difficulty in swallowing 
capacity. In patients with radical chemoradiation therapy the incidence of 
dysphagia is approximately 50 % and this is greatly reduced when treated with 
IMRT compared to conventional radiation therapy.(59)(52) Several attempts 
have been made to reduce radiation therapy doses to swallowing muscles to 
minimise the functional problem of dysphagia. 
 
Dysphagia is a common complication associated with radiation therapy in the head 
and neck cancers. With clinical trials trying to improve local control with different 
fractionation schedules and concurrent chemo radiation therapy, the toxicity of 
mucositis followed by dysphagia became increasing common.(55)  Although increase 
toxicities following these intensified treatments could be recorded in CTC criteria, 
objective measures for assessment of complications were not done routinely during 
  
earlier times. A number of clinician administered questionnaire was started to review 
the complications and functional impairments following concurrent chemo radiation 
therapy(60). Objective measurements of voice, speech and swallowing functions were 
also conducted with the help of video fluoroscopic assessment(61)(62). 
 
3.8. DYSPHAGIA 
 
Dysphagia can be described as swallowing disorder resulting from neurological or 
physiological impairment of the oral, pharyngeal or esophageal mechanisms.(63) 
Normal swallow has four coordinated steps as follows:  
a. Oral preparatory phase 
b. Oral transit phase 
c. Pharyngeal phase  
d. Esophageal phase 
The first three of these are known as oropharyngeal phase. 
During the oral preparatory phase food is crushed and mixed with saliva to form a 
bolus which is positioned on the tongue for transport. For solids, the food is 
positioned with the help of the tongue and mixed with saliva. The pharynx and larynx 
are at rest during this time. The airway is open and normal free breathing continues 
During the second phase, the bolus prepared gets ready for the transit. The tongue 
creates an anterior and posterior propulsion movement that helps the bolus to move 
  
towards the pharynx. During this movement the sensory receptors of the oropharynx 
and the tongue get stimulated and swallowing reflex gets initiated. As the food 
viscosity thickens greater muscle activity is required to squeeze the food back. Oral 
transit phase typically lasts for 1-1.5 second and increases with the increased viscosity 
of the food. 
Swallow reflex: As soon as food reaches the anterior faucial pillars at level of 
valleculae, the pharyngeal swallow gets stimulated with the help of sensory receptors 
that reaches the medulla and the pharyngeal motor pattern is initiated.  For the 
younger individuals the faucial pillars are the most sensitive area where as for older 
individuals the middle of the base of the tongue is the most sensitive area. 
During the third phase, a number of simultaneous and coordinated activities take place 
that helps in swallowing. First the soft palate stretches back to close the 
velopharyngeal port and prevent the reflux of food contents into the nasal cavity. This 
is followed by elevation and anterior movement of the hyoid bone and the larynx. The 
anterior movement of the larynx helps in opening of the esophagus and elevation of 
the hyoid protects the airway. Closure of the various laryngeal structures begins in the 
below upwards. Epiglottis inverts and come in contact to prevent the airway, the 
pharyngeal muscles contracts. Once the food is directed around the epiglottis, there is 
relaxation the esophageal sphincter, the pharyngeal phase ends and breathing is 
initiated. 
 
 
  
3.8.1. SWALLOWING ABORMALITY SECONDARY TO RADIATION THERAPY:  
The most important complication in patients having dysphagia after chemoradiaton 
therapy is aspiration. (64) Nguyen et al has reported that prevalence of sever aspiration 
in patients having dysphagia is almost 33%. Eisbruch et al also reported that post 
chemo radiation therapy, one of the most common reasons for morbidity is aspiration 
pneumonia.(65) 
Dysphagia can occur due to abnormalities in oral preparatory and pharyngeal phase: 
Dysphagia in the oral preparatory phases can be due to the following 
 Limitations due to closure of lip 
 Loss of cheek muscles after surgery 
 Trismus 
 Weakness of tongue movements due to disease 
 Decreased sensation  
 Delay in initiating the food preparation 
 Decreased saliva post radiation therapy  
 
Dysphagia in pharyngeal phases can occur due to  
 Edema in the epiglottis, slower movement and inversion 
 Decreased laryngeal movement and elevation  
 Decreased opening of cricopharyngeus muscle and increased pharyngeal 
residue 
  
One important reason for dysphagia, but less mentioned in literature is the formation 
of stricture in the hypopharyngeal region. The risk factors for this hypopharyngeal 
stricture include female sex, twice daily radiation and hypopharyngeal malignancy. 
The efficacy of dilatations has limited benefits.(66) 
 
3.8.2. RISK FACTORS FOR POST RADIATION SWALLOWING ABNORMALITIES 
 
There are several risk factor identified to cause dysphagia in patients with head and 
neck radiation therapy. Structures within the radiation port as well as the technique of 
radiation therapy influence the chances of dysphagia. 
In 2002, Eisbruch et al,(65) aimed to assess the swallowing functions objectively, in 
locally advanced head and neck cancers. The study concluded that after chemo 
radiation therapy there was significant swallowing dysfunction that was associated 
with aspiration in these groups of patients. Video fluoroscopy was the validated 
method for assessing the swallowing function allowing viewing and recording of the 
structures and dynamics of the swallowing process. Examinations were performed and 
interpreted by a radiologist and a speech-language pathologist. Each subject was asked 
to swallow multiple trials of various food consistencies in varying amounts during the 
swallowing assessment. The examinations were recorded, and analysis of the three 
phases of swallowing - oral, pharyngeal, and esophageal- was subsequently assessed 
with focus on food bolus manipulation, passage, motility and timing(67).  
 
  
Thus the objective and subjective methods to assess early and late toxicities in patients 
with locally advance head and neck cancers undergoing radiation therapy came into 
practice. With these assessment tools, early and late pharyngeal toxicities became a 
limiting factor for intensification of treatment with dose escalation in conventional 
radiotherapy and chemotherapy.  
 
Radiation therapy with IMRT technique became one of the major tools to reduce the 
toxicities. With IMRT, it was possible to produce highly conformal dose distribution, 
and reduce dose to the oral mucosa, thereby limiting the chances of dysphagia. 
Several studies showed that IMRT significantly reduced the rate of dysphagia(68). 
Study by Feng et al showed that there was dose-volume- effect relationship with 
IMRT treatment and reducing the doses to the pharyngeal constrictors can reduce 
dysphagia and aspiration.(69) 
Levendag et al (70)also showed that there exist a dose effect relationship between dose 
to the pharyngeal constrictor muscles and dysphagia. Dysphagia can be minimised by 
reducing dose to the pharyngeal constrictor muscles. 
Eisbruch et al in 2004(65)(71) showed that swallowing assessment showing video 
fluoroscopic abnormalities were attributable to the dysfunction of the circular 
pharyngeal constrictors, longitudinal pharyngeal muscles, suprahyoid muscles that 
pull the hyoid-laryngeal complex superiorly and the muscles that pull the base of the 
tongue backward. Out of all these, the circular pharyngeal constrictors and larynx 
were the major cause that limits the swallowing function. Post radiation therapy 
assessment with MRI showed that there was significant thickening noted, representing 
  
oedema and fibrosis to the pharyngeal constrictor muscles. This was confirmed by 
further studies that assessed radiological changes post radiation therapy in head and 
neck cancers(72). 
The epiglottis, aryepiglotic folds, arytenoids, true and false vocal cords also 
coordinate in swallowing function to  prevent aspiration(73). The laryngeal closure 
reflex mediated through the superior laryngeal nerve is an important protective 
mechanism against aspiration and this is absent in many patients with head and neck 
cancers(67). The sensation of food particles entering larynx provides a vital 
mechanism to prevent aspiration by evoking a cough and adductor response. This 
mechanism is affected in many patients undergoing radiation therapy and thus has a 
higher chance of aspiration followed by pneumonia. 
Apart from the pharyngeal constrictors and larynx, no radiologic changes in MRI were 
noted in other structures that can cause video fluoroscopic changes for swallowing 
dysfunction. The circular pharyngeal constrictors and the laryngeal adductors which 
lie close to the mucosa and submucosa are primarily affected after radiation therapy.  
There is also loss of elasticity of the muscle after radiation therapy, with accumulation 
of pro-inflammatory cytokines that can explain the video fluoroscopic 
abnormalities.(65) 
After the dysphagia and aspiration related structures were identified, several studies 
assessed the correlation between the dose delivered to these organs and the severity of 
dysphagia.(74) Study by Anderson et al(75) aimed to validate the Quantec 
recommendations for dose to larynx during IMRT to prevent acute dysphagia. This 
  
study showed that restricting the doses to constrictor reduces the chances of dysphagia 
in patients undergoing radiation therapy. Study by Bhide et al aimed to see the 
correlation between dose to the pharyngeal constrictors and impact of late dysphagia 
on Quality of life. (76) This study however didn‟t show any significant correlation 
between the dose to pharyngeal constrictors and patient reported or observer assessed 
dysphagia. 
 
3.8.3. COMPLICATIONS OF DYSPHAGIA 
 
The most important complication of dysphagia is aspiration that leads to pneumonia. 
Dysphagia can also lead to chronic bronchial irritation that leads to chronic cough. 
Pneumonia following aspiration can be serious and can lead to deaths in patient 
having severe dysphagia.(77) 
Late and chronic dysphagia leads to the use of tube feedings that may limit the 
nutritional demand of patients. Chronic and late dysphagia leads to poor quality of life 
and worsening of overall well being of the patient. 
 
  
  
3.8.4. PREVENTION, TREATMENT AND REHABILATATION 
 
Prevention to dysphagia involves treatment with IMRT that can spare the swallowing 
structures or reduce the dose to pharyngeal constrictors. Early detection of dysphagia 
can help to prevent serious side effects of aspiration by alternative feeding procedure 
and neck rehabilitation exercises. There are several ways like postural techniques, 
motor exercises, swallowing manoeuvres and changes in diet that can help patients 
improving dysphagia.(77) 
 
3.9. ASSESSMENT OF DYSPHAGIA 
 
Patients with head and neck cancer often experience complaints of dysphagia. Patients 
can also develop this complaint at the end of treatment due to the side effects of the 
treatment. The severity of dysphagia depends on various factors like size and location 
of cancer, nature of surgery and reconstruction and radiation therapy.  The symptoms 
that patient experience may be (78) 
a. Multiple swallows to clear the food  
b. Throat clearing while eating  
c. Pain and dryness whole eating  
d. Coughing or choking 
There are various ways for assessment of dysphagia.(77) The subjective method is a 
way of assessment of impact of dysphagia on quality of life (QOL). There are various 
  
ways of subjective assessment with the help of questionnaires that are developed and 
validated to address the problem of dysphagia. The objective assessment of dysphagia 
can be done by Video fluoroscopy study of swallowing (VFSS), modified barium 
swallow study (MBSS),functional endoscopic evaluation of swallowing 
(FEES).(67)(77) 
 
SUBJECTIVE ASSESSMENT 
 
The subjective assessment is based on the rationale that along the tumour control rate, 
overall survival rate, there are several problems that impact the quality of life in 
patients with head and neck cancers. One of the most popular tool to assess quality of 
life in head and neck cancer is the FACT-H&N score that reports quality of life in 
patients with laryngeal cancer.(79) Quality of life was also assessed by developing 
QOL-RTI that was valid and reliable tool for the assessment of patients with head and 
neck cancer undergoing radiation therapy. (80) 
The European Organisation for research and treatment of cancer quality of life 
Questionnaire (EORTC QOL) H&N35 developed a questionnaire to assess the quality 
of life in head and neck cancer patients.(81)  This questionnaire was used and validated 
in many trials(82)(83) and the recent update started that with the advent of 
multimodality treatment, several new modifications need to be considered for the 
EORTC QOL H&N35.(84)  The results from the questionnaire in EORTC QOL H&N 
35 showed that compared to conventional radiation therapy, treatment with IMRT had 
  
significant better outcome in sense of global QoL, physical well being, swallowing, 
speech, dry mouth, feeling ill etc. 
However, this questionnaire lacked dysphagia specific assessment. Hence to assess 
impact of dysphagia on quality of life, MD Anderson Dysphagia Inventory (MDADI) 
was developed. (85)It was adopted and validated in several studies to assess the quality 
of life in patients with dysphagia in head and neck cancers.(86)(87) 
The MDADI had 20 questions that assessed the global functioning, functional, 
emotional and physical aspect of daily activities in patients with dysphagia.  Each 
question had 5 choices and an overall higher MDADI score represented better day to 
day functioning and better quality of life (QoL) in patients with head and neck 
cancers. The questionnaire also had 3 specific questions that assessed the severity of 
dysphagia. (85) 
This MDADI was also adopted by Bhide et al, that assessed the correlation between 
dose to the pharyngeal constrictors and quality of life with dysphagia following  
chemoradiation therapy in head and neck cancers.(76) The study showed that patients 
undergoing chemoradiation therapy for head and neck cancers had dysphagia evident 
from the questionnaire and there was significant correlation between the objective 
assessment and MDADI. (74)(88)Several other studies also adopted the MDADI for 
assessment of QoL in patient with Dysphagia, undergoing treatment with chemo 
radiation therapy.(70)(89)(90) 
  
 
OBJECTIVE ASSESSMENT 
The objective assessment of dysphagia is commonly performed by video fluoroscopy 
swallowing study (VFSS) or Functional Endoscopic Evaluation of Swallowing 
(FEES).(91) 
The Video fluoroscopy examination of swallowing provides real time visualization of 
the oral cavity, oropharynx, laryngo-pharynx, and esophagus while using various 
consistencies and volume of barium coated materials. These coated food materials are 
ingested and their movements through the oral and pharyngeal cavities are viewed on 
monitor in the radiology suite.  VFSS is an excellent tool for assessment of 
swallowing functions and defining functional deficits and degree of aspiration. 
However VFSS has several disadvantages. First of all, the procedure is done in 
Radiology suite that required fluoroscope, monitor and skilled personnel all of which 
can be very expensive. There are also risk of radiation exposure to staff and 
appropriate positioning and adequate cognitive functioning are essential for VFSS 
assessment. With these limitations FEES became more popular and it was well 
tolerated, easy to perform with less complications like discomfort, gagging , 
vomiting.(92) 
Several studies have showed that assessment of swallowing by FESS was well 
accepted tool for assessment of dysphagia.(93)Kelly et al showed that severity of 
penetration aspiration scale in patients can be better evaluated with FEES than VFSS. 
(94)The study by Rao et al aimed to determine the sensitivity and specificity value for 
  
different parameters like pharyngeal residue and laryngeal penetration also confirmed 
that FEES is comparable to VFSS for assessment of dysphagia. Hence FEES is 
considered a standard tool for assessment of swallowing and aspirations. (95) 
 
The FEES assessment established by Langmore et al is quite a comprehensive 
evaluation of swallowing function and has mainly three components 
a. Structural movements, sensory status and anatomic support of swallowing  
b. Ability to swallow solid food and liquid 
c. Response to different alterations of the path , the way bolus is swallowed 
The assessment of FEES is done in outpatient clinic and reported as described in the 
policy statement by the Royal College of Speech and Language Therapists. It provides 
direct visualization of different anatomical structures like Nasopharynx, base of the 
tongue, vocal cords and larynx. The important functions like management of 
secretions, muscular functions of pharyngeal constrictors can be assessed along with 
identifications of pooling, laryngeal penetration, spillage, aspiration and laryngo- 
pharyngeal reflux.(96) 
  
  
  
4. METHODS AND MATERIALS 
 
This is a prospective observational study conducted in Department of Radiotherapy, 
Christian Medical College (CMC). Patients diagnosed to have head and neck cancers 
without any complaints of dysphagia and planned for treatment with IMRT were 
included into the study according to the following criteria. 
Inclusion Criteria: 
1. Patients with age more than 18 years  
2. Patients diagnosed to have biopsy proven malignancy of head and neck cancers 
3. Planned for radical radiotherapy with or without chemotherapy 
4. Planned for post operative radiotherapy with or without chemotherapy 
5. Radiation therapy with intensity modulated radiation therapy (IMRT) 
6. Willing for evaluation of their swallowing function with FEES 
7. No baseline swallowing dysfunction 
8. No evidence of disease in the pharyngeal constrictors 
 
Exclusion Criteria: 
1. Patient with prior radiotherapy 
2. Patient planned with conventional radiotherapy 
3. Patient with carcinoma Nasopharynx or Hypo pharynx 
4. Patient with histology of lymphoma, sarcoma. 
 
  
The proposed study was presented in the Institutional Review Board (IRB) which 
includes Research committee and Ethics Committee and approval was obtained (copy 
enclosed). 
 
4.1. STUDY DESIGN: 
 
This study assessed the quality of life in patients diagnosed to have head and neck 
cancers undergoing radiation therapy with IMRT. Patients were subjectively assessed 
for dysphagia with MDADI and objectively with FEES before starting of radiation 
therapy, midway and end of radiation therapy. The radiation dose to the pharyngeal 
constrictors was correlated with the swallowing dysfunction in FEES and the 
MDADI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Study work flow: 
 
 
 
 
 
 
4.2. SAMPLE SIZE: 
 
Patients diagnosed with head and neck cancers and planned for radiation therapy with 
IMRT were screened. Among the 22 patients screened, 14 patients who met the 
inclusion and exclusion criteria were selected for the study. These 14 patients 
underwent treatment with radiation therapy with or without chemotherapy from March 
2015 to August 2015 by IMRT technique either as radical treatment or as 
postoperative therapy. Seven patients were not included as they had evidence of 
involvement of the pharyngeal constrictors in the planning CT scan and one patient 
was not included as she had history of prior radiation. 
Correlation of the dose to the pharyngeal constrictors with findings 
in FEES and MDADI 
End of treatment evaluation of swallowing dysfunction
Subjective: by MDADI Objective: By FEES
Mid treatment evaluation of swallowing dysfunction
Subjective: by MDADI Objective: By FEES
Baseline evaluation of swallowing dysfunction
Subjective: by MDADI Objective: By FEES
Patients diagnosed- Head and Neck Carcinoma( oral cavity, oropharynx, larynx 
, paranasal sinus) and have consented to be a part of the study 
Planned for radiation therapy with or without chemotherapy 
  
4.3. RADIATION THERAPY: 
 
Patient received radiation therapy either as definitive intent or post operative setting. 
They were explained regarding the process of radiation therapy with IMRT technique, 
costs and benefits, related side effects and time duration of therapy. They were 
explained the side effects of chemotherapy with Cisplatin if indicated, after clearance 
from Cardiology for the same. Audiogram was performed to assess any underlying 
hearing loss, before chemotherapy. Metastatic work up and dental clearance was 
obtained for all patients. In post operative setting, radiation therapy was initiated only 
after healing of the surgical scar with an average period of 2- 3 weeks. 
 
Radiation therapy planning 
Immobilization: Patients were positioned supine on the simulator couch and Orfit 
Raycast was used for immobilization. The 3 points were marked on the Raycast on the 
simulator using the anterior and lateral lasers. Planning CT was carried out with the 
same set up. CT scan was obtained 3mm slice thickness from vertex to T4 vertebral 
level, with IV contrast. The planning CT was imported to the Eclipse Contouring 
stations for segmentation. Images were registered and segmentation of the targets 
volumes and organ at risks were done using standard guidelines.(97) 
 
Contouring of the constrictor muscle: Fig 4.1 
Contouring or segmentation of the pharyngeal constrictors were done on the planning 
CT according to the guidelines as described by Eisbruch et al. (69) and Bhide et al.(76) 
Three parts of the pharyngeal constrictors were identified. Each of the pharyngeal 
  
constrictors was outlined as an arch shaped structure with concavity facing anteriorly, 
in line with the mucosa. Posterior border of each of the muscles was prevertebral 
muscle. This was done using 3mm brush in the Eclipse contouring tool. 
 
Superior constrictor (SC) was outlined from the caudal tips of the pterygoid plates and 
the caudal extent was superior end of the hyoid. Middle constrictor (MC) was outlined 
from superior end of the hyoid bone to inferior end of the hyoid bone. Inferior 
constrictor (IC) was outlined from inferior aspect of the hyoid to inferior end of the 
cricoid cartilage. The three pharyngeal constrictor structures were combined to create 
total constrictor unit (TC). The segmentation of the pharyngeal constrictors can be 
seen as below:  
  
Segmentation of Pharyngeal constrictor muscles 
 
                   
 
 
                     
 
 
 
                 
 
Fig: 4.1 Figure illustrates the segmentation of Superior, Middle and Inferior Constrictor muscle in axial and 
sagittal view. 
 
Superior Constrictor Middle Constrictor 
Superior Constrictor 
Inferior Constrictor 
Inferior Constrictor Middle Constrictor 
  
 
Picture showing treatment plan  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2 Figure illustrates the treatment plan for a patient diagnosed with Carcinoma Supra glottis 
a. Plan assessment in Planning System in different views 
b. Beams arrangement view for the treatment plan 
c. Phase I volume 
d. Phase II volume 
 
 
 
 
 
 
a b 
c d 
  
 
 
Picture showing dose distribution  
 
 
 
 
 
 
 
 
 
 
 
 
             
 
 
 
 
Fig. 4.3 Figure ilustrates plan evaluation for a patient diagnosed with Carcinoma Supra glottis 
a. Dose Colour Wash in Coronal Section 
b. Dose Colour Wash in Sagittal Section 
c. Dose Colour Wash in Axial Section with 3 CT markers and plan isocenter 
d. Cumulative Dose Volume Histogram for plan assessment 
 
a b 
c d 
  
 
 
Dose prescription:  
The prescribed dose was 70 Gy in 35 fractions at 2 Gy per fraction, 5 days per week, 
for patients with definitive intent chemo radiation therapy. Post postoperative dose 
prescribed was 60 Gy to 66Gy, depending upon the risk factors. In all patients, the 
plans addressed prescription goals as the highest priority, where as critical organ 
dosimetric goals (apart from spinal cord and brainstem) were considered as secondary. 
Optimization was done to keep minimum dose to the normal organs at risk (OARs). 
 
Chemotherapy: 
Patient received chemotherapy with Cisplatin concurrently either weekly once at dose 
of 40mg/m2 or three weekly once with dose of 100mg/m2.Antiemetic and pre and 
post chemotherapy hydration schedule were delivered according to the standard of 
care.(98) 
 
Radiation therapy treatment process: (Fig 4.4) 
Patients were treated with Varian CLINAC 2100 machine, from Monday through 
Friday. Cone beam CT was obtained for setup verification on day 1, 2, 3 and weekly 
once. Patients were reviewed weekly once for assessment of reactions.  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
                  
 
                                         Fig. 4.4 Patient treated in CLINAC for IMRT 
 
 
 
 
                              
                                 Fig. 4.5 Flexible Naso-pharyngo-Laryngo scope used for FEES 
  
 
4.4. SWALLOWING ASSESSMENT WITH MDADI QUESTIONNAIRE 
 
Patient reported dysphagia was assessed with MDADI. Patients were asked to fill the 
MDADI that has 20 questions related to dysphagia before starting of radiation 
therapy, midway and end of radiation therapy. The 20 questions assessed 4 
components like global, emotional, functional and physical aspect that reflects the 
Quality of life. An overall MDADI score of less than 60 represents patients having 
dysphagia ( Bhide et al) (76) The MDADI had 3 dysphagia specific questions within 
MDADI Questionnaire. The 3 questions were: 
P6 (Question no 7): Swallowing takes great effort 
P7 (Question no10): It takes me longer to eat because of my swallowing problem 
P8 (Question no 8): I cough when I try to drink liquids 
The scale for the questions ranged from 1- 5, 1 representing severe complaints while 5 
representing no complaints. A score of less than 3 was considered as dysphagia 
(according to Bhide et al) 
 
4.5. SWALLOWING ASSESSMENT WITH FEES 
 
Swallowing dysfunction and dysphagia were evaluated with Functional Endoscopic 
Evaluation of Swallowing (FEES). The FEES assessment was conducted before 
starting of radiation therapy as baseline. FEES were done midway during radiation 
therapy and end of radiation therapy. (Fig 4.5) 
 
  
Patient undergoing FEES was explained in detail regarding the procedure and possible 
side effects. The evaluation was done in the outpatient clinic in the presence of ENT 
specialists, Speech therapist and Nurse. The patient was instructed to sit straight and 
through one nostril the Endoscope was inserted. No local anaesthesia was used. 
 
In the first part, the assessment was done for the anatomical landmarks as the Flexible 
Endoscope views the nasopharynx, oropharynx and larynx. Any pooling of saliva in 
the valleculae or pyriform sinus was noted. The patient was instructed to vocalise a 
sound „eee‟ and assessed for closure of the vocal cords.  
 
In the second part, water mixed with edible green dye was given to the patient to 
swallow.  Assessment of swallowing of semisolid was done with Cerelac mixture. 
Assessment of swallowing with the Endoscope was done with direct visualisation of 
the pooling of coloured liquid or food after multiple swallows. 
 
Assessment of the swallowing was done by the combined opinion from ENT 
specialist and the Speech specialist. A FEES proforma based on the FEES assessment 
performed in NHS London was followed to document the FEES findings. 
 
 
 
 
 
  
 FEES assessment 
 
 
 
 
           
 
 
  
 
 
  
            
 
 
 
 
 
Fig. 4.4 Figure illustrates the FEES findings 
 
a. Normal vocal cord with breathing at rest 
b. Vocal cord adducted position (to assess mobility  of cord) 
c. Mild pooling of green coloured liquid after swallowing 
d. Mild food residue after swallowing 
 
 
 
 
a b 
c d 
  
Data collection  
 
Treatment plans of patients were retrieved from the Eclipse planning system. The 
mean, maximum, and minimum doses to individual muscles and as a total combined 
unit were noted. Also „Vd‟ denoting Volume in percentage receiving the dose d was 
obtained for each muscle and the total combined unit. 
 
MDADI score was collected at the start of radiation therapy, midway and end of 
radiation therapy as shown in the Appendix. The score can range from 0 to 100, where 
0 denotes severe dysphagia and 100 means no dysphagia.  
 
FEES assessment was done with the following component 
a. Anatomical assessment  
b. Secretion rating  (Score 0 to2, 0-normal, 2-most severe) 
c. Penetration-aspiration scale(Score 1to8, 1-normal,8- most severe) 
d. Consistency outcome with semi-solid and liquid (Score 0 to2, 0-normal,  
2-severe) 
 
The FEES assessment score was calculated at the start of radiation therapy, midway 
and end of radiation therapy as shown in the Annexure. 
 
  
4.6. STATISTCAL ANALYSIS 
The data from the Questionnaire, FEES assessment, and dose parameters were 
obtained and entered into Microsoft Excel sheet. Frequencies and percentages were 
calculated for the discrete variables. 
 
For correlation between the dose to the pharyngeal constrictors and FEES assessment, 
patients were divided into two groups. One group had dysphagia and the other group 
without dysphagia, as assessed by the FEES in various ways. This was correlated to 
the Maximum dose and Mean dose to the pharyngeal constrictors using Wilcoxon 
rank sum test. For correlation between score from the questionnaire and the Maximum 
and Minimum doses to the pharyngeal constrictors, Pearson Correlation was used.  
 
  
  
5. RESULTS 
 
This study group consisted of 14 patients who underwent treatment with radiation 
therapy with or without chemotherapy either as the primary modality or in the 
postoperative setting, from March 2015 to August 2015 by IMRT technique meeting 
the inclusion and exclusion criteria. 
The results are summarized under the following headings 
 
1. Demographic details of the patients 
 
2. Results of MDADI score  
 
3. Results of FEES assessment  
 
4. Dose characteristics to pharyngeal constrictor muscles 
 
5. Correlation of pharyngeal constrictor dose with Dysphagia (by FEES) 
 
6. Correlation of MDADI score with Dysphagia (by FEES) 
 
7. Correlation of pharyngeal constrictor dose with MDADI score 
 
 
 
 
 
 
  
  
5.1. DEMOGRAPHIC DETAILS OF THE PATIENTS 
 
                             Distribution of patients according to age  
 
                          
 
Fig 5.1.1 Histogram showing distribution of patients according to age group 
Majority of the patients were in the 41 to 60 age group 
 
 
 
                                
                              Distribution of patients according to sex 
 
 
                              
 
 
Fig 5.1.2 Pie chart showing distribution of patients according to age 
Majority of the patients were males with a male to female ratio of 6:1 
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           Distribution of patients according to different sites of cancer 
 
                      
 
Fig 5.1.3 Pie chart showing distribution of patients according to the site of cancer 
Majority of the patients included in the study had carcinoma of the buccal mucosa followed by carcinoma of the 
supraglottis, oral cavity and oropharynx 
 
 
 
 
Distribution of patients according to the modality of treatment received 
 
 
 
 
 
Fig: 5.1.4 Distribution of patients according to the modality of treatment received 
Among the 14 patients,8 had surgery followed by appropriate post operative adjuvant radiotherapy or chemo 
radiation therapy and 6had definitive chemo radiation therapy. Out of the 8 patients who underwent surgery, 2 
patients received chemo radiation therapy and 6 patients received only radiation therapy 
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Distribution of patients according to histology of the malignancy 
 
                     
 
 
Fig 5.1.5 Pie chart showing distribution of patients according to the histology 
Among the 14patients, 13 had squamous cell carcinoma (SQCC) and only1patient had adenocarcinoma (ADC). 
 
 
 
         Distribution of patients according to the dose of radiation received  
 
 
              
 
 
Fig 5.1.6 Distribution of the patients according to the dose of radiation received Among the 14 patients 
included, 6 received 60Gy and the remaining 8 received more than 66Gy. 
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5.2. OVERALL MDADI QESTIONNAIRE SCORE 
 
Scores obtained from overall MDADI Questionnaire, assessed before, midway 
and end of radiation therapy 
 
 
 
Fig 5.2.1 Box plot illustrating the overall MDADI score assessed before, midway and end of radiation therapy 
The median score for all patients from the questionnaire, before radiation therapy was 99(range 65 to 100), this 
median score decreased to 68 (range 38 to 100) midway during radiation therapy and the score further decreased 
to 50 (range 42 to 82) at the end of radiation therapy.  
 
 
Distribution of patients having dysphagia according to score obtained from 
overall MDADI questionnaire 
 
 
                     
 
 
 
Fig 5.2.2 illustrates the distribution of patients having dysphagia according to the overall score from the 
MDADI questionnaire. Patients were classified as having dysphagia if the overall score from the MDADI was 
below 60. No patients had dysphagia prior to starting radiation therapy, 4 out of 14 patients (28%) had 
dysphagia midway during radiation therapy which increased to 9 out of 14 (64%) patients at the end of radiation 
therapy 
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Distribution of patients according to the score obtained from the 3 dysphagia 
specific questions within MDADI Questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 
5.2.3 illustrates the distribution of patients according to the scores obtained from the3 dysphagia specific 
questions within MDADI Questionnaire that was assessed before, midway and end of the radiation therapy. 
 
The 3 questions were: 
P6 (Question no 7): Swallowing takes great effort 
P7 (Question no10): It takes me longer to eat because of my swallowing problem 
P8 (Question no 8): I cough when I try to drink liquids 
 
The scale for the questions ranged from 1- 5, 1 representing severe complaints while 5 
representing no complaints. A score of less than 3 was considered as dysphagia. For 
P6 (Swallowing takes great effort) all 14 patients had score of either 4 or 5 prior to 
starting radiation therapy.  Midway during radiation therapy 42% (6/14) patients had a 
score of 2 (representing dysphagia) and at the end of radiation therapy 12 out of 14 
  
(85%) patients had a score of either 1 or 2. This shows that the number of patients 
developing severity of dysphagia as assessed by the question P6 (swallowing takes 
great effort) increased with increasing doses of radiation and this occurred in 42% 
(6/14) of patients midway and increased to 85% (12/14) by end of radiotherapy. 
 
For P7 (It takes me longer to eat because of my swallowing problem) majority- 78% 
(11/14) of the patients had a score of 4 or 5 and 21% (3/14) had a score of 1 or 2prior 
to starting of radiation therapy. 
 
Midway during radiation therapy 9 out of 14 (64%) had a score of either 1 or 2 and at 
the end of radiation therapy 10 out of 14 (71%) had a score of either 1 or 2. This 
shows that majority(64% - 9/14) of patients developed severity of dysphagia as 
assessed by the question P7 (It takes me longer to eat because of my swallowing 
problem)  by midway of radiation therapy and only 1 more by end of radiation therapy 
(71% - 10/14). 
For P8 (I cough when I try to drink liquids) only 8% (1/14) patient had a score less 
than 3, rest 92% (13/14) had a score of either 4 or 5 prior to starting radiation therapy. 
28% (4/14) had a score less than 3 mid way during radiation therapy and 50% (7/14) 
had a score of less than 3 at the end of radiation therapy. This shows the number of 
patients developing severity of dysphagia as assessed by the question P8 (I cough 
when I try to drink liquids) increases with increasing doses of radiation and this 
occurred in 28% (4/14) of patients midway and increased to 50% (7/14) by end of 
radiation therapy. 
 
  
 
5.3. FEES ASSESSMENT:  
 
Distribution of patients according to the findings in FEES assessed before, 
midway and at the end of radiation therapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3.1 Figure illustrates the results of the FEES assessment with 4 ways for the assessment of dysphagia. 
They were as follows: 
P1- Secretion rating (range 0- 2, 2=severe problems) 
P2-Penetration-aspiration scale (range 1-8, 8=severe problems) 
P3-Swallowing with liquid (range 0- 2, 2=severe problems) 
P4-Swallowing with semisolid (range 0- 2, 2=severe problems)  
 
 
For P1 (assessment with secretion rating) none had dysphagia prior to starting of 
radiation therapy, 50% (7/14) had mild dysphagia (score 1) midway during radiation 
therapy and at the end of radiation therapy 42% (6/14) had mild dysphagia (score 1) 
and 21% (3/14) had severe dysphagia (score 2). 
 
Colour – represents the scale/severity of dysphagia, for P2 (Penetration Aspiration scale) none 
had scored more than 2, hence none colour code shown 
Area of the Pie represents number of patients with dysphagia 
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For P2 (assessment with penetration aspiration scale) none had dysphagia prior to 
starting of radiation therapy or midway during radiation therapy. 1 out of 14 had score 
2 at the end of Radiation therapy (score 2 indicates –food material enters airway, 
remains above the vocal folds and is ejected out from the airway) 
 
For P3 and P4 (assessment with swallowing for liquids and semisolids) 2 out of 14 
patients had mild dysphagia for liquids prior to starting of radiation therapy (score 1) 
and 3 out of 14 patients had mild dysphagia for semi solids prior to starting of 
radiation therapy(score of 1). 
 
Midway during radiation therapy, 50% (7/14) of the patients had mild dysphagia for 
both liquids and semisolids (score 1), and this included the 2 patients who had mild 
dysphagia, prior to starting radiation therapy. 14% (2/14) of the patients had severe 
dysphagia for both liquids and semisolids (score 2) and these 2 patients had no 
abnormality (score 0) prior to starting radiation therapy. Rest 36% (5/14) had no 
problems with swallowing. 
 
At the end of radiation therapy, 21% (3/14) of the patients had mild dysphagia for 
both liquids and semisolids (score 1), while 57% (8/14) of the patients had severe 
dysphagia for both liquids and semisolids (score 2). Remaining 21% (3/14) of the 
patients had no problems at the end of radiation therapy. 
 
  
 
5.4. DOSIMETRIC CHARACTERISTICS 
 
Volume of the pharyngeal constrictor muscles and dose received 
                          
 
 
Fig 5.4.1 Box plots that illustrates the volume of the pharyngeal constrictor muscles for all patients segmented 
for the treatment  
 
 
For all patients, the volume of Superior constrictor muscle ranged from 2.7cc to 7.2cc 
with a median of 4.6cc. The volume varied according to the length of the neck of each 
patient. For Middle constrictor, the volume of muscle receiving dose for all patients 
ranged from 0.6cc to 2.2cc with a median of 1.7cc. For Inferior constrictor, the 
volume of muscle receiving dose for all patients ranged from 1.4cc to 3cc with a 
median of 2.55cc. For Total constrictor unit, the volume of muscle receiving dose for 
all patients ranged from 5.4cc to 12cc with a median of 9.3 cc. This shows that there is 
more variation in the volume of the superior constrictor depending on the length of the 
neck, as compared to the middle and inferior constrictor. 
 
 
 
 
 
SC: Superior constrictor 
MC: Middle constrictor 
IC: Inferior constrictor 
TC: Total constrictor unit 
  
Radiation therapy dose received by individual muscles during radiation therapy 
Superior Constrictor Muscle dose  
                                                             
Fig 5.4.2 Fig shows the minimum, mean and maximum doses to superior constrictor muscles for all patients. 
The dose to superior constrictor was minimum of 29 Gy and maximum of 74 Gy. The mean dose to superior 
constrictor was minimum of 41Gy and maximum 72Gy 
 
Middle Constrictor Muscle dose  
                                                             
Fig 5.4.3 Fig shows minimum, mean and maximum doses to middle constrictor muscles for all patients. The 
dose to middle constrictor was minimum of 0 Gy and maximum of 74 Gy. The mean dose to middle constrictor 
was minimum of 39 Gy and maximum of 72 Gy. 
 
Inferior Constrictor Muscle dose  
                                                                
Fig 5.4.4 Fig shows minimum, mean and maximum doses to middle constrictor muscles for all patients. The 
dose to inferior constrictor was minimum of 0 Gy and maximum of 74 Gy. The mean dose to superior 
constrictor was minimum of 37 Gy and maximum of 72Gy. 
 
  
  
Distribution of radiation doses received by pharyngeal constrictor muscles 
according to the site of malignancy  
 
 
Diagram showing the Maximum doses to each respective pharyngeal constrictor 
muscle and total combined unit according to site of cancer 
 
 
 
 
 
Fig 5.4.5 Figure shows Maximum doses to constrictor muscles for all patients according to the site of 
malignancy  
 
For patients with sinonasal carcinoma and buccal mucosa the median value of the 
maximum doses to all pharyngeal constrictors was below 60 Gy. For oropharyngeal 
carcinoma, oral cavity and supraglottis, the median value of maximum doses to all the 
pharyngeal constrictors was more than 60 Gy. 
 
 
  
Diagram showing the mean doses to each respective pharyngeal constrictor 
muscle and total combined unit according to site of cancer 
 
 
 
 
 
 
 
Fig 5.4.6 Figure shows Mean doses to constrictor muscles for all patients according to the site of malignancy.  
 
 
For sinonasal carcinoma and buccal mucosa the median value of the mean dose to 
pharyngeal constrictors was below 55Gy. For oropharyngeal carcinoma, oral cavity 
and supraglottis, the median value of mean doses to all the pharyngeal constrictors 
was more than 55Gy. 
 
 
 
 
 
 
  
Diagram showing the V10 to V70 for each of the pharyngeal constrictors  
 
 
 
SUPERIOR CONSTRICTOR V10 TO V70 
 
 
 
 
 
Fig 5.4.7 Fig illustrates the Volume (%) of the SC receiving dose„d‟. The median V50 is almost 100% for all 
patients. The median Vd gradually decreases with increase in dose „d‟, as seen from median V55 (90%) to 
median V70 (0%). 
 
 
 
 
 
MIDDLE  CONSTRICTOR  V10 TO V70 
 
 
 
 
 
 
Fig 5.4.8 Fig illustrates Volume (%) of the MC receiving dose„d‟. The median V50 is almost 100% for all 
patients. The median Vd gradually decreases with increase in dose„d‟, as seen from median V60 (70%) to median 
V70 (0%) 
 
 
 
 
 
 
 
  
INFERIOR  CONSTRICTOR  V10 TO V70 
 
 
 
 
 
 
 
Fig 5.4.9 Fig illustrates the Volume (%) of the IC receiving dose„d‟. The median V45 is almost 100% for all 
patients. The median Vd gradually decreases with increase in dose „d‟, as seen from median V50 (80%) to 
median V70 (0%) 
 
 
 
TOTAL  CONSTRICTOR  UNIT V10 TO V70 
 
 
 
 
 
 
Fig 5.4.10 Fig illustrates the Volume (%) of the TC receiving dose„d‟. The median V45 is almost 100% for all 
patients. The median Vd gradually decreases with increase in „d‟, as seen from median V50 (80%) to median V70 
(0%) 
 
 
 
 
 
 
 
  
  
5.5. CORRELATION OF DOSE WITH DYSPHAGIA (Assessed by FEES) 
 
In the diagrams below, Y axis show the dose to the respective pharyngeal constrictor 
muscles and X axis show patients with and without dysphagia (blue –no dysphagia 
and green –dysphagia). P- Value signifies the statistical significance. 
 
Diagram to show correlation between maximum dose to each of the pharyngeal 
constrictor muscles and dysphagia at the end of radiation therapy (assessed by 
swallowing liquids and semisolids in FEES, P3 and P4) 
 
 
 
 
 
 
 
 
Fig 5.5 figure illustrating the correlation with maximum doses to Pharyngeal constrictor muscles and dysphagia 
as assessed by swallowing liquids and semisolids by FEES (P3) and (P4) 
 
 
0, 1, 2 represents scale of dysphagia assessed by 
swallowing Liquids &Semisolids by FEES (P3&P4) 
a b
  a 
c d 
  
In fig 5.5.a the maximum doses to Superior Constrictor in the group of patients with 
dysphagia (score of 2) ranged from 62Gy to 74Gy with a median dose of 70.5 Gy, 
while maximum dose to SC in the group of patients without dysphagia (score of 0, 1) 
ranged from 48Gy to 70Gy with a median dose of 59.5 Gy. When the median dose to 
SC between the two groups (with and without dysphagia) was compared, there was a 
difference with statistical significance (p=0.01). 
 
In fig 5.5.b the maximum doses to Middle Constrictor in the group of patients with 
dysphagia (score of 2) ranged from 60 Gy to 74 Gy with a median dose of 71 Gy, 
while maximum dose to MC in the group of patients without dysphagia (score of 0, 1) 
ranged from 48Gy to 70Gy with a median dose of 57.5 Gy. When the median dose to 
MC between the two groups (with and without dysphagia) was compared, there was a 
difference with statistical significance (p=0.01). 
 
 
In fig 5.5.c the maximum doses to Inferior Constrictor in the group of patients with 
dysphagia (score of 2) ranged from 58 Gy to 74 Gy with a median dose of 69 Gy, 
while maximum dose to IC in the group of patients without dysphagia (score of 0, 1) 
ranged from 46 Gy to 68Gy with a median dose of 55.5 Gy. When the median dose to 
IC between the two groups (with and without dysphagia) was compared, there was a 
difference with statistical significance (p=0.006). 
 
 
  
In fig 5.5.d the maximum doses to Total Constrictor unit in the group of patients with 
dysphagia (score of 2) ranged from 62 Gy to 74 Gy with a median dose of 71 Gy, 
while maximum dose to IC in the group of patients without dysphagia (score of 0, 1) 
ranged from 48 Gy to 70 Gy with a median dose of 59.5 Gy. When the median dose to 
IC between the two groups (with and without dysphagia) was compared, there was a 
difference with statistical significance (p=0.02) 
 
 
Similar analysis was also done by comparing the median value of the maximum doses 
between the group with dysphagia (score 1, 2) and without dysphagia (score of 0). 
Results showed no statistical significance between the two groups 
 
 
Analysis was done by comparing maximum dose to each of the pharyngeal constrictor 
muscles and dysphagia at the end of radiation therapy (assessed by Secretion Rating 
of FEES, P1) Results showed no statistical significance between the two groups 
 
 
 
 
 
 
 
  
Diagram to show correlation between MEAN dose to each of the pharyngeal 
constrictor muscles and dysphagia at the end of radiation therapy (assessed by 
swallowing liquids and semisolids in FEES, P3 and P4) 
 
 
 
 
 
 
 
 
Fig 5.6 Figure illustrating the correlation with mean doses to Pharyngeal constrictor muscles and dysphagia as 
assessed by swallowing liquids and semisolids by FEES (P3) and (P4) 
 
In fig 5.6.a the Mean doses to Superior Constrictor in the group of patients with 
dysphagia (score of 2) ranged from 53 Gy to 72 Gy with a median dose of 63 Gy, 
while Mean dose to SC in the group of patients without dysphagia (score of 0, 1) 
ranged from 41Gy to 67 Gy with a median dose of 49 Gy. When the median dose to 
SC between the two groups (with and without dysphagia) was compared, there was 
difference and with statistical significance (p=0.02). 
0, 1, 2 represents scale of dysphagia assessed by 
swallowing Liquids &Semisolids by FEES (P3&P4) 
a b 
c d 
  
In fig 5.6.b the Mean doses to Middle Constrictor in the group of patients with 
dysphagia (score of 2) ranged from 50 Gy to 72 Gy with a median dose of 63 Gy, 
while Mean dose to MC in the group of patients without dysphagia (score of 0, 1) 
ranged from 39 Gy to 71 Gy with a median dose of 54 Gy. When the median dose to 
MC between the two groups (with and without dysphagia) was compared, there was 
no difference and no statistical significance (p=0.17). 
In fig 5.6.c the Mean doses to Inferior Constrictor in the group of patients with 
dysphagia (score of 2) ranged from 35 Gy to 64 Gy with a median dose of 56 Gy, 
while Mean dose to IC in the group of patients without dysphagia (score of 0, 1) 
ranged from 36 Gy to 55 Gy with a median dose of 46 Gy. When the median dose to 
IC between the two groups (with and without dysphagia) was compared, there was no 
difference and no statistical significance (p=0.16). 
 
In fig 5.6.d the Mean doses to Total Constrictor unit in the group of patients with 
dysphagia (score of 2) ranged from 52Gy to 67 Gy with a median dose of 63 Gy, 
while Mean dose to TC in the group of patients without dysphagia (score of 0, 1) 
ranged from 39 Gy to 62 Gy with a median dose of 50 Gy. When the median dose to 
IC between the two groups (with and without dysphagia) was compared, there was a 
no difference with no statistical significance (p=0.22) 
 
Similar analysis was also done by comparing the median value of the Mean dose 
between the group with dysphagia (score 1, 2) and without dysphagia (score of 0). 
Results showed no statistical significance between the two groups. 
  
Diagram to show correlation between Maximum dose to each of the pharyngeal 
constrictor muscles and dysphagia at the end of radiation therapy (assessed by 
penetration and aspiration scale in FEES, P2 
 
 
 
 
 
 
 
 
Fig 5.7 Figure illustrating the correlation with Maximum doses to Pharyngeal constrictor muscles and 
dysphagia as assessed according to Penetration- aspiration scale FEES (P2). 
 
 
Only 1 out of 14 patients had a score of 2 when assessed by FEES with penetration 
aspiration scale. (Score 2 represents food material enters the airway, remains above 
the vocal folds and is ejected from the airway). No patients had scored more than 2 on 
assessment with FEES. 
 
In fig 5.7.a the Maximum dose to Superior Constrictor in the patients with dysphagia 
(score of 2) was 74 Gy, while Maximum dose to SC in the group of patients with 
score of 1) ranged from 48 Gy to 74 Gy with a median dose of 63 Gy. When the 
median dose to SC between the two groups was compared, there was no difference 
and no statistical significance (p=0.08). 
A B C 
1, 2 represents scale of dysphagia assessed by penetration aspiration scale 
by FEES (P2) No patients had score more than 2. (Scale range 1to 8) 
  
 
In fig 5.7.b the Maximum dose to Middle Constrictor in the patient with dysphagia 
(score of 2) was 74 Gy, while Maximum dose to MC in the group of patients with 
score of 1) ranged from 48 Gy to 72 Gy with a median dose of 64 Gy. When the 
median dose to MC between the two groups was compared, there was no difference 
and no statistical significance (p=0.07). 
 
In fig 5.7.c the Maximum dose to Inferior Constrictor in the patient with dysphagia 
(score of 2) was 74 Gy, while Maximum dose to IC in the group of patients with score 
of 1) ranged from 46 Gy to 72 Gy with a median dose of 62 Gy. When the median 
dose to IC between the two groups was compared, there was no difference and no 
statistical significance (p=0.07) 
 
Therefore no results showed statistical significant (p >0.05) for Maximum dose to 
Superior constrictor, Middle constrictor, inferior constrictor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Diagram to show the correlation of Vd (Volume in percent receiving the dose ‘d’ ) 
for Superior Constrictor muscle and dysphagia as assessed by Swallowing 
LIQUID & SEMISOLIDS by FEES (P3) and (P4) 
 
In the diagrams below – Y axis show the Volume receiving dose D (Vd) for respective 
pharyngeal constrictor muscles and X axis – two groups in two colours (blue –no 
dysphagia and green –dysphagia). P- Value signifies the statistical significance. 
 
SUPERIOR CONSTRICTOR  
 
 
 
 
 
 
 
Fig 5.8 Figure illustrating the correlation with Vd of Superior Constrictor muscle and dysphagia as assessed by 
Swallowing LIQUID & SEMISOLIDS by FEES (P3) and (P4).   
 
The median volume (in percent) receiving dose„d‟ in patients with dysphagia (score 2, as assessed by 
swallowing liquids or semisolids in FEES) was compared to the median volume (in percent) receiving the same 
dose„d‟ in patients without dysphagia (score 0,1 assessed by FEES).The Figure shows that in V65 and V70, i.e. 
the Volume receiving dose 65 Gy and 70 Gy respectively was higher in the patients with dysphagia compared to 
the other group and this was also statistically significant. Statistical significant (p <0.05) for Superior 
constrictor V65 and V70. 
 
 
 
 
 
0, 1, 2 represents scale of dysphagia assessed by 
swallowing Liquids &Semisolids by FEES (P3&P4) 
  
MIDDLE CONSTRICTOR 
 
Diagram to show the correlation of Vd (Volume in percent receiving the dose‘d’) 
for Middle Constrictor and dysphagia as assessed by Swallowing LIQUID & 
SEMISOLIDS by FEES (P3) and (P4) 
 
 
 
 
 
 
 
 
 
Fig 5.9 Figure illustrating the correlation with Vd of Middle Constrictor and dysphagia as assessed by 
Swallowing LIQUID & SEMISOLIDS by FEES (P3) and (P4).   
 
The median volume (in percent) receiving dose„d‟ in patients with dysphagia (score 2, as assessed by 
swallowing liquids or semisolids in FEES) was compared to the median volume (in percent) receiving the same 
dose„d‟ in patients without dysphagia (score 0,1asessed by FEES) The Figure shows that in V55 V60 V65 and V70, 
i.e. the Volume( in percent) receiving dose 55 Gy, 60 Gy, 65 Gy and 70 Gy respectively was higher in the 
patients with dysphagia compared to the other group , that were also statistically significant (p<0.05) in all the 
above mentioned figures. 
 
 
 
 
 
0, 1, 2 represents scale of dysphagia assessed by 
swallowing Liquids &Semisolids by FEES (P3&P4) 
  
INFERIOR CONSTRICTOR 
 
Diagram to show the correlation of Vd (Volume in percent receiving the dose‘d’ ) 
for Inferior Constrictor and dysphagia as assessed by Swallowing LIQUID & 
SEMISOLIDS by FEES (P3) and (P4) 
 
 
 
 
 
 
 
 
 
Fig 5.10 Figure illustrating the correlation with Vd of Inferior Constrictor and dysphagia as assessed by 
Swallowing LIQUID & SEMISOLIDS by FEES (P3) and (P4).   
 
The median volume (in percent) receiving dose„d‟ in patients with dysphagia (score 2, as assessed by 
swallowing liquids or semisolids in FEES) was compared to the median volume (in percent) receiving the same 
dose„d‟ in patients without dysphagia (score 0,1asessed by FEES). The Figure shows that in V 50,V55, V60 ,V65 
and V70, i.e the Volume ( in percent) receiving dose 50 Gy, 55 Gy, 60 Gy, 65 Gy and 70 Gy respectively was 
higher in the patients with dysphagia compared to the other group , that were also statistically significant 
(p<0.05) in all the above mentioned figures. 
 
0, 1, 2 represents scale of dysphagia assessed by 
swallowing Liquids &Semisolids by FEES (P3&P4) 
  
5.6. CORRELATION OF MDADI SCORE WITH DYSPHAGIA (assessed by 
FEES) 
                  
 
 
 
 
 
Fig 5.6.1 Figure illustrating the correlation with MDADI score assessed at the end of radiation therapy and 
dysphagia as assessed by Secretion Rating by FEES (P1).  
 
 
Patients who had dysphagia (score of 2, as assessed with secretion rating in FEES) 
had MDADI score ranged from 44 to 46 with median score of 45. Patients who had no 
dysphagia (score of 0, 1 as assessed with secretion rating in FEES) had MDADI score 
ranged from 42 to 82 with median score of 66. When the median score between the 
two groups were compared there was difference that was statistical significant with p 
value of 0.02. This shows that patients who had dysphagia (assessed by FEES) also 
reported poor quality of life with MDADI score below 60. 
 
  
0, 1, 2 represents scale of dysphagia assessed by 
Secretion Rating by FEES (P1) 
  
                   
 
 
 
 
 
Fig 5.6.2 Figure illustrating the correlation with MDADI Questionnaire score assessed at the end of radiation 
therapy and dysphagia assessed by Swallowing LIQUID & SEMISOLIDS by FEES (P3) and (P4) 
 
 
Patients who had dysphagia (score of 2, as assessed with swallowing liquid and 
semisolid in FEES) had MDADI score ranged from 42 to 74 with median score of 48. 
Patients who had no dysphagia (score of 0, 1 as assessed swallowing liquid and 
semisolid in FEES) had MDADI score ranged from 48 to 75 with median score of 70. 
When the median score between the two groups were compared there was difference 
that was statistical significant with p value of 0.02. This shows that patients who had 
dysphagia (assessed by FEES) also reported poor quality of life with MDADI score 
below 60. 
  
0, 1, 2 represents scale of dysphagia assessed by swallowing 
Liquids &Semisolids by FEES (P3&P4) 
  
5.7. CORRELATION OF MDADI QUESTIONNAIRE WITH DOSE TO 
PHARYNGEAL CONSTRICTORS 
 
Correlation of MDADI score with dose to Superior Constrictor 
  
       
 
Fig 5.7.1 Figure illustrating the correlation with MDADI score assessed at the end of radiation therapy and 
Maximum and Mean doses to the Superior constrictor muscle. In both the above figures it can be seen that 
with the increase in Maximum and Mean doses to the SC, there was worsening of the MDADI scores. These 
figures represent the negative correlation, and show that with increase in doses to the muscle there is decrease in 
MDADI scores. 
 
 
Correlation of MDADI score with dose to Middle Constrictor 
            
 
Fig 5.7.2 Figure illustrating the correlation with MDADIscore assessed at the end of radiation therapy and 
Maximum and Mean dose to the Middle constrictor muscle.  
In both the above figures it can be seen that with the increase in Maximum and Mean doses to the MC, there 
was worsening of the MDADI scores. These represent the negative correlation, and show that with increase in 
doses to the muscle there is decrease in MDADI scores 
 
  
 
 
Correlation of MDADI score with dose to Inferior Constrictor 
               
 
Fig 5.7.3 Figure illustrating the correlation with MDADI Questionnaire score assessed at the end of radiation 
therapy and Maximum and Mean dose to the Inferior constrictor muscle 
 
In both the above figures it can be seen that with the increase in Maximum and Mean doses to the IC, there was 
worsening of the MDADI scores. These represent the negative correlation, and show that with increase in doses 
to the muscle there is decrease in MDADI scores 
 
  
  
6. DISCUSSION 
 
Radiation therapy is one of the main modalities of treatment for head and neck cancers 
either alone or in combination with chemotherapy or surgery. Patients undergoing 
radiation therapy can have significant problems during and post treatment in the form 
of mucositis, xerostomia and dysphagia which affects their quality of life. Although 
IMRT can help in reducing dose to the salivary glands and reduce xerostomia and 
dysphagia, its role in preventing dysphagia by reducing dose to pharyngeal structures 
and constrictor muscles is controversial. 
This study was conducted therefore in a prospective manner and aimed to assess the 
correlation between the radiation dose to the pharyngeal constrictors with subjective 
and objective assessment of swallowing function in patients with head and neck 
cancer undergoing treatment with radiation therapy with IMRT technique. At present 
in view of time constraints, results and analysis have been conducted based on acute 
findings (mid and end of Radiation therapy assessment). Long term follow up to 
assess the late changes in dysphagia observed following radiation therapy should be 
undertaken. 
 
In this study the majority of the study population were in the age group of 41 years to 
60 years and the male to female ration was 6:1. Among the 14 patients 8 had radiation 
therapy in the adjuvant setting and other 6 had definitive radiation therapy. Majority 
of the patients (8 out of 14) received radiation dose more than 60 Gy. 
 
  
All patients in our study had no complaints of dysphagia and no radiological 
involvement of pharyngeal constrictors prior to radiation therapy. 
According to the study by Bhide et al.(76), MDADI score below 60 reflected poor 
quality of life related to dysphagia. Similar findings were also noted in our study, 
where 4 patients had MDADI score less than 60 midway during radiation therapy and 
9 patients at the end of radiation therapy. This reflects the impact of dysphagia in 
quality of life in patients with head and neck cancers, during radiation therapy. 
 
The same above mentioned author also studied the correlation between various 
MDADI scores (like Global score, physical score, emotional score and dysphagia 
specific scores) and the objectively assessed grade of dysphagia.  In his study there 
was a significant correlation between MDADI score and grade of dysphagia which 
was also seen in our study. The patients in our study were also assessed with FEES 
and classified into two groups. It was found that those patients, who were assessed to 
have significant dysphagia by FEES, also had low MDADI score reflecting poor QoL 
due to dysphagia. 
Feng et al study (69)(71) showed that patient reported swallowing function was 
significantly associated with the mean pharyngeal constrictor dose and among the 
pharyngeal constrictors, superior constrictor had the highest correlation. In our study 
similar correlation was seen with the superior constrictors only.  
It was also observed that there was a correlation between patient reported MDADI 
score and the maximum dose and mean dose to all the constrictors, similar to the study 
by Feng et al. It was noted in our study that with increase in maximum or mean dose 
  
to pharyngeal constrictor muscles there was worsening of quality of life due to 
dysphagia as reflected by the worsening MDADI score. However, in our study none 
of these correlations were statistically significant and this may be due to small number 
of patients included. 
Also, in the study by Feng et al, all patients who developed aspiration by video fluoro 
scopy (VFS) were found to have mean dose to the pharyngeal constrictor muscles 
above 60Gy. A study by Jensen et al on 35 patients with VFS showed that mean dose 
less than 60Gy resulted in low risk of aspiration. In contrast to the above studies, 
Bhide et al and Laan et al(99) concluded that the exact relationship between the 
radiation doses to the constrictor and post radiotherapy dysphagia is still unclear. 
 
In our study the correlation between the dose to the pharyngeal constrictors and 
dysphagia was assessed by FEES. Patients who developed severe dysphagia (as 
assessed by swallowing liquids and semisolids) had a higher mean dose to superior 
constrictor muscle that was statistically significant. 
 
In addition to this, our study also showed that patients who had dysphagia also had a 
higher maximum dose to all the pharyngeal constrictors (SC, MC and IC) which was 
statistically significant. 
 
According to Anderson et al study (75) that validated the Quantec recommendations 
showed that V50 less than 30% resulted in decreased acute toxicity of Grade 3 
dysphagia.  Our study showed that patients, who had dysphagia assessed by FEES, 
had V65 more than 40% for superior constrictor, V65 more than 60% for middle 
constrictor and V55 more than 50% for inferior constrictor. 
  
LIMITATION 
The study population was small with 14 patients.  More number of patients would 
help in better statistical analysis to correlate the dose and dysphagia assessment. 
 
A significant number of patients had surgery, followed by adjuvant radiation therapy. 
These patients were included as they did not have complaints of dysphagia and 
fulfilled all other inclusion criteria. But on analysis this group were found to have 
poor oral phase of swallowing on FEES that might affect the overall swallowing 
function and therefore these patients should be looked at separately.  
 
During radiation therapy patients often develop mucositis as a part of treatment. This 
can affect the assessment with MDADI questionnaire. Follow up assessments with the 
same questionnaire can help to distinguish between mucositis and dysphagia. 
 
 
  
  
7. CONCLUSION 
 
1. In this study it was found that the correlation with the maximum dose received 
by all the pharyngeal constrictors and mean dose to superior constrictor was 
significantly associated with dysphagia assessed by FEES. 
 
2. Among the pharyngeal constrictors, superior constrictor was the one which was 
found to have the most significant association with dose and development of 
dysphagia as assessed with FEES.  
 
 
3. The study also found worsening of the overall quality of life with complaints of 
dysphagia (assessed with the MDADI score) that correlated with findings of 
FEES, with statistical significance. 
 
4. The worsening of the quality of life as reflected by MDADI score, correlated 
with maximum and mean doses to the pharyngeal constrictors, with statistical 
significance. 
 
Longer follow up with both subjective and objective assessment is necessary to better 
understand the long term effect of late dysphagia in patients undergoing radiation 
therapy for head and neck cancers. 
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9. ANNEXURES 
 
INFORMATION SHEET AND CONSENT FORM 
Christian Medical College, Vellore 
Department of Radiation therapy 
Patient’s Information sheet 
Association between the radiation dose to the pharyngeal constrictors and 
swallowing dysfunction and patients’ quality of life following chemo 
irradiation for head and neck cancers 
 
You are being requested to participate in a study which aims to find an association between 
the radiation dose delivered to the pharyngeal constrictor muscles and its effect on the 
swallowing capability in patients of head and neck cancer undergoing treatment with radical 
chemo irradiation. 
What does this study do? 
This is an observational study to assess the quality of life and swallowing difficulty in 
patients diagnosed to have head and neck cancer undergoing treatment with radiation 
therapy and chemotherapy. It has been seen that patients develop difficulty in swallowing 
during the course of radiation therapy which significantly affects their quality of life. 
In this observational study, we would like to assess patients’ quality of life by using simple 
questionnaires and endoscopy procedures and then evaluate the effect of swallowing 
difficulty in these patients due to the dose of radiation therapy delivered to the muscles 
helping in swallowing. 
This will help us in the future by reducing dose to these muscles helpful in swallowing and 
will thus help in improving patients’ quality of life 
Does this study have any side effects? 
This is an observational study with no particular side effects.  
If you take part what will you have to do? 
If you agree to participate in this study, you will be given a dysphagia score questionnaire 
form to be filled up before your treatment, during the middle of your treatment and also in 
the subsequent routine follow up visits at 6 weeks and 3 months. You will also have to 
undergo an endoscopic evaluation of your swallowing ability of liquids and solids, along with 
the filling up of the questionnaire. 
  
All other treatments that you are already on will be continued and your regular treatment 
will not be changed during this study. One additional endoscopy will be done for the 
evaluation of your swallowing capability during the course of the treatment and you will not 
have to pay for that endoscopic procedure. 
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your usual 
treatment at this hospital in any way. 
What will happen if you develop any study related injury? 
Since this is an observational study, no particular study related side effects are expected. 
However, during the course of endoscopy for the evaluation of dysphagia, you may 
experience some pain or uneasiness. 
Will you have to pay for the study?  
This is an observational study and there is no change in the standard treatment of care. You 
need not pay anything more than the regular treatment charges as applicable for the 
radiation therapy and the chemotherapy.  
What happens after the study is over? 
You will be advised to have regular checkups at the specified intervals as advised which will 
be every 3 months in the first one year, every six months for the next two years and yearly 
thereafter. 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be identified 
by name in any publication or presentation of results. However, your medical notes may be 
reviewed by people associated with the study, without your additional permission. 
 
 
 
 
 
 
 
 
 
  
INFORMED CONSENT FORM 
A study to find the association between the radiation dose to the pharyngeal constrictors 
and swallowing dysfunction and patients’ quality of life following chemo irradiation for 
head and neck cancers 
Subject’s Initials: __________________  
Subject’s Name: _________________________________________ 
Date of Birth / Age: ___________________________ 
For illiterate subjects : As read to me 
(i)  I confirm that I have read and understood the information sheet dated ____________ 
for the above study and have had the opportunity to ask questions.  
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected.  
(iii)  I understand that the Sponsor of the clinical trial, others working on the 
Sponsor’s behalf, the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or 
published.  
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). 
(v)  I agree to take part in the above study. 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
Signatory’s Name: _________________________________         Signature:  
Or 
 
 
 
  
Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
Signature or thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name & Address of the Witness: ______________________________ 
 
 
 
 
 
 
 
 
 
  
Association between the radiation dose to the pharyngeal constrictors and 
swallowing dysfunction and patients’ quality of life following chemo 
irradiation for head and neck cancers 
FEES ASSESSMENT REPORT  
 
Patient Name:  
Hospital Number:  
Date of Birth /age  
Date of Assessment:  
 
Diagnosis:  
 
Other relevant Medical / Surgical History:  
 
 
ASSESSMENT INFORMATION  
 
A NASOPHARYNX COMMENTS  
Anatomy                     WNL / ONL _____________________________  
Symmetry of Closure   WNL / ONL _____________________________  
Degree of closure        WNL / ONL _____________________________  
Closure pattern    Circular / Coronal _____________________________  
  
 
B BASE OF TONGUE  
Anatomy                         WNL / ONL _____________________________  
Symmetry of movement WNL / ONL _____________________________  
Range of movement       WNL / ONL _____________________________  
 
C HYPOPHARYNX  
Anatomy                          WNL / ONL _____________________________  
Symmetry                        WNL / ONL _____________________________  
Range of movement         WNL / ONL _____________________________  
 
D LARYNX  
Anatomy WNL / ONL _____________________________  
Symmetry at rest WNL / ONL _____________________________  
Symmetry of closure & phonation WNL / ONL _____________________________  
 
 
 
 
 
 
 
 
 
 
  
E AIRWAY PROTECTION (Murray 1999)  
Breath holding not achieved  
Transient breath holding with glottis open  
Sustained breath holding with glottis open  
Transient true fold closure  
Sustained true fold closure  
Transient true and ventricular fold closure  
Sustained true and ventricular fold closure  
Vocal fold closure on voluntary cough 
 
F SECRETION RATING (Murray 1999)  
O Normal rating: ranges from no visible secretions anywhere in the hypopharynx, to some 
transient secretions visible in the valleculae and pyriform sinuses. These secretions 
are not bilateral or deeply pooled.  
1 Any secretions evident upon entry or following a dry swallow in the protective structures 
surrounding the laryngeal vestibule that are bilaterally represented or deeply pooled. 
This rating would include cases in which there is transition in the accumulation of 
secretions during observation segment.  
2 Any secretions that change from “1”” to a “3” rating during the observation period.  
3 Most severe rating. Any secretions seen in the area defined as laryngeal vestibule. 
Pulmonary secretions are included if they are not cleared by swallowing or coughing 
by the close of the segment.  
 
 
G PENETRATION – ASPIRATION SCALE (Rosenbek 1996)  
1 Material does not enter the airway  
2 Material enters the airway, remains above the vocal folds and is ejected from the airway  
3 Material enters the airway, remains above the vocal folds, and is not ejected from the 
airway  
4 Material enters the airway, contacts the vocal folds, and is ejected from the airway  
5 Material enters the airway, contacts the vocal folds, and is not ejected from the airway  
6 Material enters the airway, passes below the vocal folds, and is ejected into the larynx or 
out of the airway  
7 Material enters the airway, passes below the vocal folds, and is not ejected from the trachea 
despite effort  
8 Material enters the airway, passes below the vocal folds, and no effort is made to eject  
 
 
Consistencies Outcome  
 
Thin syrup (liquid) 
_____________________________________________________________  
Thick cerelac 
(semisolid)_____________________________________________________________  
 
 
COMMENTS 
 
 
  
Association between the radiation dose to the pharyngeal constrictors and 
swallowing dysfunction and patients’ quality of life following chemo 
irradiation for head and neck cancers 
 
                     
This questionnaire asks for your views about your swallowing ability. This 
Information will help us understand how you feel about swallowing. 
 
The following statements have been made by people who have problems with 
their swallowing. Some of the statements may apply to you. 
 
Please read each statement and circle the response which best reflects your 
experience in the past week. 
 
1. My swallowing ability limits my day-to-day activities 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
2. I am embarrassed by my eating habits 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
3. People have difficulty cooking for me 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
4. Swallowing is more difficult at the end of the day 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
5. I do not feel self-conscious when I eat 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
6. I am upset by my swallowing problem 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
7. Swallowing takes great effort 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
8. I do not go out because of my swallowing problem 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
9. My swallowing difficulty has caused me to lose income 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
10. It takes me longer to eat because of my swallowing problem 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
  
 
11. People ask me “Why can‟t you eat that?” 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
12. Other people are irritated by my eating problem 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
13. I cough when I try to drink liquids 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
14. My swallowing problems limit my social and personal life 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
15. I feel free to go out to eat with my friends, neighbors and relatives 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
16. I limit my food intake because of my swallowing difficulty 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
17. I cannot maintain my weight because of my swallowing problem 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
18. I have low self-esteem because of my swallowing problem 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
19. I feel that I am swallowing a huge amount of food 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
20. I feel excluded because of my eating habits 
Strongly Agree Agree No Opinion Disagree Strongly Disagree 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
  
 
 
 
  
 
  
 
 
 
 
  
 
 
DATA 
FEES DATA 
 
 
MDADI DATA 
 
 
DOSIMETRY 
a. 
 
 
PRE-S-P1 PRE-S-P2 PRE-S-P3 PRE-S-P4 MID-S-P1 MID-S-P2 MID-S-P3 MID-S-P4 END-S-P1 END-S-P2 END-S-P3 END-S-P4 RYLES TUBE
0 1 0 0 0 1 0 0 0 1 0 0 0
0 1 0 0 0 1 0 0 0 1 0 0 0
0 1 0 0 0 1 0 0 0 1 0 0 0
0 1 1 1 0 1 1 1 1 1 2 2 1
0 1 0 0 0 1 1 1 0 1 1 1 0
0 1 0 0 1 1 1 0 1 1 1 1 0
0 1 0 0 1 1 2 2 1 1 2 2 1
0 1 0 0 1 1 1 1 2 2 2 2 1
0 1 0 0 0 1 2 2 1 1 2 2 0
0 1 0 0 1 1 1 1 2 1 2 2 1
0 1 0 0 1 1 0 0 1 1 2 1 1
0 1 1 1 1 1 1 1 2 1 2 2 1
0 1 0 0 1 1 1 1 1 1 1 2 0
0 1 0 1 0 1 1 1 1 1 2 2 0
PRE-Q-TOTAL PRE-Q-GLOBALPRE-Q-EMOTIONALPRE-Q-FUNCTIONALPRE-Q-PHYSICALPRE-Q-P6 PRE-Q-P7PRE-Q-P8 MID-Q-TOTALMID-Q-GLOBALMID-Q-EMOTIONALMID-Q-FUNCTIONALMID-Q-PHYSICALMID-Q-P6 MID-Q-P7 MID-Q-P8 END-Q-TOTAL END-Q-GLOBALEND-Q-EMOTIONALE D-Q-FUNCTIONALEND-Q-PHYSICALEND-Q-P6 END-Q-P7 END-Q-P8
100 5 30 25 40 5 5 5 74 5 26 15 28 4 5 2 74 4 24 21 25 4 4 4
100 5 30 25 40 5 5 5 100 5 30 25 40 5 5 5 82 4 25 19 34 4 4 4
70 4 22 20 24 4 2 2 70 2 22 20 26 4 2 4 66 2 20 23 21 2 2 4
81 4 26 17 34 4 5 5 38 2 12 10 14 2 1 2 42 2 12 13 16 2 1 2
100 5 30 25 40 5 5 5 86 4 26 23 33 4 4 4 75 4 24 19 28 2 2 4
100 5 30 25 40 5 5 5 82 4 25 21 32 4 4 4 48 2 16 13 17 2 2 2
100 5 30 25 40 5 5 5 75 4 21 20 30 4 2 4 74 4 21 20 29 2 3 4
94 5 29 24 36 5 5 5 66 4 20 18 24 2 2 4 45 2 14 11 18 2 2 3
65 5 19 13 28 4 1 4 53 1 13 18 21 4 1 4 58 1 15 21 21 1 1 4
98 5 30 24 39 5 5 5 50 4 17 12 17 2 2 1 46 2 16 13 15 2 2 2
100 5 30 25 40 5 5 5 65 4 19 17 25 2 2 4 50 4 13 15 18 2 2 2
96 5 30 25 36 4 2 5 60 2 21 15 22 2 2 4 44 2 12 14 16 1 1 4
86 4 25 22 35 4 4 4 53 2 16 15 20 2 2 2 50 2 16 15 17 2 2 3
100 5 30 25 40 5 5 5 80 5 25 20 30 4 4 5 58 3 15 20 20 2 2 3
SC-V10 SC-V20 SC-V30 SC-V40 SC-V45 SC-V50 SC-V55 SC-V60 SC-V65 SC-V70 MC-V10 MC-V20 MC-V30 MC-V40 MC-V45 MC-V50 MC-V55 MC-V60 MC-V65 MC-V70
100 100 100 100 100 100 100 100 98 0 100 100 100 100 100 100 96 82 68 2
100 100 100 70 26 5 1 0 0 0 100 100 100 34 0.3 0 0 0 0 0
100 100 100 100 100 100 100 99 0 0 100 100 100 100 100 100 98 79 0 0
100 100 100 100 99 78 45 28 0 0 100 100 100 100 100 100 97 61 0 0
100 100 100 93 84 56 1 0 0 0 100 100 100 100 100 40 1.3 0 0 0
100 100 100 100 100 95 81 14 0 0 100 100 100 100 100 99 51 0 0 0
100 100 100 100 100 100 100 100 6 0 100 100 100 100 100 100 100 97 10 0
100 100 100 100 100 100 88 77 75 69 100 100 100 100 100 100 100 100 100 100
100 100 100 100 100 94 87 74 62 0.6 100 100 100 99 91 83 72 62 52 1.4
100 100 100 100 100 82 34 13 0 0 100 100 100 100 100 56 4.8 0 0 0
100 100 100 100 100 100 100 100 100 99 100 100 100 100 100 100 100 96 84 60
100 100 100 100 100 100 100 100 100 98 100 100 100 100 100 100 100 89 69 25
100 100 100 100 96 84 62 20 0 0 100 100 100 100 100 100 56 5.6 0 0
93 88 82 68 53 34 28 24 18 8 100 100 100 100 100 100 100 100 100 97
  
b. 
 
 
c. 
 
 
 
 
 
 
 
IC-V10 IC-V20 IC-V30 IC-V40 IC-V45 IC-V50 IC-V55 IC-V60 IC-V65 IC-V70 TC-V10 TC-V20 TC-V30 TC-V40 TC-V45 TC-V50 TC-V55 TC-V60 TC-V65 TC-V70
100 100 100 100 100 88 39 11 3 0 100 100 100 100 100 96 83 72 67 1
100 100 100 9 0 0 0 0 0 0 100 100 100 49 14 3 0 0 0 0
100 100 100 100 100 74 11 0 0 0 100 100 100 100 100 91 71 63 0 0
100 100 100 100 74 41 28 18 0 0 100 100 100 100 91 70 48 30 0 0
100 100 100 100 56 12 0 0 0 0 100 100 100 96 82 43 1.5 0 0 0
100 100 95 30 12 3 0.7 0 0 0 100 100 98 79 12 3.7 0.6 0 0 0
100 100 100 100 100 100 100 98 9.7 0 100 100 100 100 100 100 100 99 24 0
100 100 100 100 100 100 80 54 44 32 100 100 100 100 100 100 88 78 74 69
100 100 55 34 25 15 9.2 4.8 0.6 0 100 100 88 82 78 71 62 53 43 0.5
100 100 100 100 98 66 18 0 0 0 100 100 100 100 98 65 17 0 0 0
100 100 100 100 100 100 100 47 29 15 100 100 100 100 100 96 99 84 77 70
100 100 100 100 100 100 50 15 4.7 0.1 100 100 100 100 100 100 88 77 71 62
100 100 100 100 100 100 30 6 0 0 100 100 100 100 98 92 51 12 0 0
100 100 100 100 100 100 100 100 100 90 96 94 91 84 77 68 65 63 60 51
SC-VOL MC-VOL IC-VOL TC-VOL SC-MIN SC-MAX SC-MEAN MC-MIN MC-MAX MC-MEAN IC-MIN IC-MAX IC-MEAN TC-MIN TC-MAX TC-MEAN
4.9 1.6 2.3 9.3 64 70 67 0 70 65 0 68 54 0 70 63
6.7 2 2.6 12 34 48 41 34 48 39 34 46 39 34 48 39
4.8 1.2 2.8 9.3 59 63 61 52 64 61 47 61 51 47 64 58
3.4 0.6 2.2 6.6 45 62 55 52 62 59 41 62 50 41 62 54
6.2 2.2 2.5 11.6 29 57 49 45 55 49 41 55 46 29 57 48
4.4 1.9 2.8 9.6 45 62 56 49 60 54 26 56 37 26 62 50
2.8 1.1 2.6 7.5 59 66 63 59 66 63 60 68 64 59 68 63
2.7 2.2 2.2 7.4 49 74 67 70 74 72 50 74 63 49 74 68
2.8 0.8 1.4 5.4 43 70 63 38 70 61 20 66 35 20 70 55
3.8 2 1.4 7.9 46 62 53 44 60 50 42 58 51 42 62 52
5 1.1 2.4 9 69 73 71 56 72 69 54 72 61 54 73 68
7.2 2 2.8 12 69 74 72 56 72 66 50 70 56 50 74 67
4.4 1.4 3 9.4 34 53 45 41 50 45 40 49 44 0 53 45
5 1.8 3 10.4 50 71 45 69 72 71 69 72 70 50 72 58
